FEATURE_phases list | FEATURE_enrollmentCount int64 | FEATURE_allocation string | FEATURE_interventionModel string | FEATURE_primaryPurpose class label | FEATURE_masking class label | FEATURE_healthyVolunteers bool | FEATURE_sex class label | FEATURE_oversightHasDmc bool | FEATURE_briefSummary string | FEATURE_detailedDescription string | FEATURE_conditions string | FEATURE_conditionsKeywords string | FEATURE_protocolPdfText string | FEATURE_numArms int64 | FEATURE_armDescriptions string | FEATURE_armGroupTypes list | FEATURE_numInterventions int64 | FEATURE_interventionTypes list | FEATURE_interventionDescriptions string | FEATURE_interventionNames string | FEATURE_numLocations int64 | FEATURE_locationDetails string | LABEL_ct_level_ade_population int64 | LABEL_sum_dosing_errors int64 | LABEL_dosing_error_rate float32 | LABEL_wilson_label int64 | METADATA_nctId string | METADATA_overallStatus class label | METADATA_completionDate date32 | METADATA_startDate date32 | METADATA_leadSponsorName string | METADATA_leadSponsorClass class label | METADATA_hasProtocol bool | METADATA_hasSap bool | METADATA_hasIcf bool | METADATA_protocolPdfLinks string | METADATA_count_Accidental drug intake by child int64 | METADATA_count_Accidental overdose int64 | METADATA_count_Accidental overdose (therapeutic agent) int64 | METADATA_count_Accidental underdose int64 | METADATA_count_Deliberate overdose int64 | METADATA_count_Dose calculation error int64 | METADATA_count_Drug administration error int64 | METADATA_count_Drug overdose int64 | METADATA_count_Drug overdose accidental int64 | METADATA_count_Extra dose administered int64 | METADATA_count_Incorrect dosage administered int64 | METADATA_count_Incorrect dose administered int64 | METADATA_count_Incorrect drug administration duration int64 | METADATA_count_Incorrect drug administration rate int64 | METADATA_count_Incorrect product administration duration int64 | METADATA_count_Intentional overdose int64 | METADATA_count_Medication error int64 | METADATA_count_Medication monitoring error int64 | METADATA_count_Multiple drug overdose int64 | METADATA_count_Multiple drug overdose accidental int64 | METADATA_count_Multiple drug overdose intentional int64 | METADATA_count_Multiple use of single-use product int64 | METADATA_count_Non-accidental overdose int64 | METADATA_count_Overdose int64 | METADATA_count_Overdose NOS int64 | METADATA_count_Overmedication int64 | METADATA_count_Prescribed overdose int64 | METADATA_count_Treatment noncompliance int64 | METADATA_count_Underdose int64 | METADATA_count_Unintentional medical device removal int64 | METADATA_count_Unintentional medical device removal by patient int64 | METADATA_wilson_lower_bound float32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[
3
] | 21 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | null | Once-daily nucleotide/nucleoside reverse transcriptase inhibitor (NtRTI/NRTI) combinations form the backbone of many regimens. Although efficacy data exists between tenofovir and the pyrimidine analogues (i.e. lamivudine and emtricitabine), recent clinical data suggests a potential interaction between tenofovir and pur... | The primary objectives of this study are to compare the virologic potency and pharmacology of TDF and ABC alone and in combination. Since it is not feasible or ethical to give mono or dual-therapy with these agents for prolonged intervals, this project was designed to take advantage of a short term drug exposure. The s... | HIV Infections | HIV nucleoside pharmacology drug-drug interaction Treatment Naive Drug resistance Drug pharmacokinetics | Prot_SAP_000.pdf:
CCTG 584
Protocol version 1.2
September 1, 2004
1
CCTG 584
Viral Dynamics and Pharmacokinetics of TDF and ABC Monotherapy versus the
Combination Therapy of TDF – ABC in HIV-Infected Treatment Naïve Patients
Sponsored by:
The University Wide AIDS Research Program (UA... | 2 | arm 1: As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone arm 2: As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone | [
1,
1
] | 2 | [
0,
0
] | intervention 1: 300 mg once daily intervention 2: 600 mg once daily | intervention 1: Tenofovir intervention 2: Abacavir | 5 | Irvine | California | United States | -117.82311 | 33.66946
Los Angeles | California | United States | -118.24368 | 34.05223
San Diego | California | United States | -117.16472 | 32.71571
San Jose | California | United States | -121.89496 | 37.33939
Torrance | California | United States | -118.34063 | 33.83585 | 21 | 0 | 0 | 0 | NCT00214890 | 1COMPLETED | 2010-04-27 | 2004-12-07 | University of California, San Diego | 7OTHER | true | true | false | https://cdn.clinicaltrials.gov/large-docs/90/NCT00214890/Prot_SAP_000.pdf | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 460 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia. | null | Schizophrenia | null | 4 | arm 1: SM-13496 40 mg was administered orally once daily. arm 2: SM-13496 80mg was administered orally once daily. arm 3: Placebo was administered orally twice daily. arm 4: Risperidone was administered orally twice daily. | [
0,
0,
2,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: Lurasidone HCl: 40 mg/day intervention 2: Lurasidone HCl: 80 mg/day intervention 3: None intervention 4: None | intervention 1: SM-13496 (lurasidone HCl) intervention 2: SM-13496 (lurasidone HCl) intervention 3: Placebo intervention 4: Risperidone | 3 | Tokyo, Etc. | N/A | Japan | 139.69171 | 35.6895
Seoul, Etc. | N/A | South Korea | 126.9784 | 37.566
Taipei, Etc. | N/A | Taiwan | 121.52639 | 25.05306 | 455 | 0 | 0 | 0 | NCT00711269 | 1COMPLETED | 2010-04-27 | 2008-06-27 | Sumitomo Pharma Co., Ltd. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 2,030 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder. | null | Urinary Bladder, Overactive | Urgency YM178 Urinary incontinence Mirabegron Micturition Frequency Urinary urgency incontinence Overactive Bladder | null | 3 | arm 1: Participants received matching mirabegron placebo tablets orally once a day for 12 weeks. arm 2: Participants received mirabegron 25 mg tablets orally once a day for 12 weeks. arm 3: Participants received mirabegron 50 mg tablets orally once a day for 12 weeks. | [
2,
0,
0
] | 2 | [
0,
0
] | intervention 1: Mirabegron tablets intervention 2: Matching mirabegron placebo tablets. | intervention 1: Mirabegron intervention 2: Placebo | 151 | Homewood | Alabama | United States | -86.80082 | 33.47177
Huntsville | Alabama | United States | -86.58594 | 34.7304
Mobile | Alabama | United States | -88.04305 | 30.69436
Chandler | Arizona | United States | -111.84125 | 33.30616
Tucson | Arizona | United States | -110.92648 | 32.22174
Tucson | Arizona | United State... | 1,305 | 0 | 0 | 0 | NCT00912964 | 1COMPLETED | 2010-04-27 | 2009-04-28 | Astellas Pharma Inc | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 57 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | null | A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control. | null | Type 2 Diabetes Mellitus (T2DM) | null | 2 | arm 1: Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks. arm 2: Participants randomized to this arm will be administered matching placebo, daily for six weeks. | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Sitagliptin tablet 100 mg, administered once daily before the morning meal. intervention 2: Matching placebo tablet, administered once daily before the morning meal. | intervention 1: Comparator: sitagliptin phosphate intervention 2: Comparator: placebo (unspecified) | 0 | null | 50 | 0 | 0 | 0 | NCT00704132 | 1COMPLETED | 2010-04-28 | 2007-02-14 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 5 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH), on the muscle, bone and fat tissues of the body. GHRH stimulates the production of growth hormone (GH), which regulates the build up of many tissues in the body, including muscles and bon... | Growth hormone (GH) is a major anabolic hormone that exerts important stimulatory effects on protein synthesis. Many of the peripheral tissue effects of GH are mediated by insulin-like growth factor I (IGF-I), produced systemically by the liver or locally in tissues in response to GH stimulation. IGF-I in turn regulate... | Elderly | Growth Hormone-Releasing Hormone Growth Hormone Insufficiency Aging Growth Hormone Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Hormones | null | 1 | arm 1: Growth Hormone-Releasing Hormone | [
0
] | 1 | [
0
] | intervention 1: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months. | intervention 1: GHRH | 2 | Baltimore | Maryland | United States | -76.61219 | 39.29038
Boston | Massachusetts | United States | -71.05977 | 42.35843 | 5 | 0 | 0 | 0 | NCT00807365 | 6TERMINATED | 2010-04-29 | 2007-12-17 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 137 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied. | null | Hepatocellular Carcinoma (HCC) | null | 1 | arm 1: no comparator to brivanib | [
0
] | 1 | [
0
] | intervention 1: Tablet, Oral, Brivanib 800 mg, once daily, until progression | intervention 1: brivanib (active) | 37 | Duarte | California | United States | -117.97729 | 34.13945
Duarte | California | United States | -117.97729 | 34.13945
Los Angeles | California | United States | -118.24368 | 34.05223
Los Angeles | California | United States | -118.24368 | 34.05223
Newark | Delaware | United States | -75.74966 | 39.68372
Miami | Flori... | 143 | 0 | 0 | 0 | NCT00355238 | 1COMPLETED | 2010-04-30 | 2006-12-31 | Bristol-Myers Squibb | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 23 | NA | SINGLE_GROUP | 0TREATMENT | 1SINGLE | false | 0ALL | false | To assess the potential for ridaforolimus to prolong the QTc interval (an effect on the electrical activity of the heart) in participants with advanced cancer. This study will be done in 2 parts. Part 1 (Pt 1) will evaluate the effect of a single 100 mg dose of ridaforolimus on QT interval in participants with advanced... | null | Metastatic or Locally Advanced Cancer | null | 1 | arm 1: \[Pt 1, Day 1\]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. \[Pt 1, Day 2\]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, particip... | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2. intervention 2: Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug. intervention 3: Part 1: A single oral d... | intervention 1: Ridaforolimus 100 mg intervention 2: Ridaforolimus 40 mg intervention 3: Placebo | 0 | null | 67 | 0 | 0 | 0 | NCT00874731 | 1COMPLETED | 2010-04-30 | 2009-04-28 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 50 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abata... | null | Active Rheumatoid Arthritis | null | 2 | arm 1: None arm 2: None | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment intervention 2: Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment | intervention 1: Abatacept intervention 2: Placebo | 10 | Brussels | N/A | Belgium | 4.34878 | 50.85045
Yvoir | N/A | Belgium | 4.88059 | 50.3279
Berlin | N/A | Germany | 13.41053 | 52.52437
Berlin | N/A | Germany | 13.41053 | 52.52437
Amsterdam | N/A | Netherlands | 4.88969 | 52.37403
Barcelona | N/A | Spain | 2.15899 | 41.38879
Barcelona | N/A | Spain | 2.15899 | 41.38879
S... | 50 | 1 | 0.02 | 1 | NCT00420199 | 1COMPLETED | 2010-05-01 | 2007-05-01 | Bristol-Myers Squibb | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.003539 | |
[
4
] | 236 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | This study will compare the efficacy and safety of treatment with pegylated-interferon alfa-2a plus ribavirin in participants with non-genotype 2/3 CHC who, after 12 weeks of study treatment, have undetectable hepatitis C virus (HCV)-ribonucleic acid (RNA) or a greater than or equal to (\>=) 2 log10 drop in HCV-RNA. Pa... | null | Hepatitis C, Chronic | null | 7 | arm 1: Participants with HCV RNA levels greater than (\>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (\>=) 15 IU/mL at Week 8, and either HCV RNA less than (\<) 15 IU/mL or \>=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys... | [
0,
0,
0,
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration. intervention 2: Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration. | intervention 1: Pegylated-interferon Alfa-2a intervention 2: Ribavirin | 23 | Milwaukee | Wisconsin | United States | -87.90647 | 43.0389
Calgary | Alberta | Canada | -114.08529 | 51.05011
Edmonton | Alberta | Canada | -113.46871 | 53.55014
Edmonton | Alberta | Canada | -113.46871 | 53.55014
Abbotsford | British Columbia | Canada | -122.25257 | 49.05798
Vancouver | British Columbia | Canada | -1... | 236 | 1 | 0.004237 | 1 | NCT00483938 | 1COMPLETED | 2010-05-01 | 2007-06-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000748 | |
[
3
] | 353 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD). | ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for AD. ELND005 may prevent or inhibit the build up of amyloid protein in the brains of AD patients.
This is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral EL... | Alzheimer Disease | null | 4 | arm 1: None arm 2: None arm 3: None arm 4: None | [
2,
1,
1,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: ELND005 matched placebo capsules for oral administration, bid for 78 weeks intervention 2: ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks intervention 3: ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks intervention 4: ELND005 capsules for ora... | intervention 1: Placebo Control intervention 2: ELND005 intervention 3: ELND005 intervention 4: ELND005 | 62 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Sun City | Arizona | United States | -112.27182 | 33.59754
Tucson | Arizona | United States | -110.92648 | 32.22174
Fresno | California | United States | -119.77237 | 36.74773
Garden Grove | California | United States | -117.94145 | 33.77391
Los Angeles | Califo... | 351 | 1 | 0.002849 | 1 | NCT00568776 | 1COMPLETED | 2010-05-01 | 2007-12-01 | OPKO Health, Inc. | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000503 | |
[
4
] | 597 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone. | null | Type 2 Diabetes | Dapagliflozin efficacy safety sulphonylurea Type 2 diabetes | null | 4 | arm 1: dapagliflozin 2.5mg + Glimepiride arm 2: dapagliflozin 5mg + Glimepiride arm 3: dapagliflozin 10mg + Glimepiride arm 4: Placebo + Glimepiride | [
0,
0,
0,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks intervention 2: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks intervention 3: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice intervention 4: rescue medication ... | intervention 1: dapagliflozin intervention 2: Glimepiride intervention 3: metformin hydrochloride intervention 4: pioglitazone hydrochloride intervention 5: Rosiglitazone | 66 | Blansko | N/A | Czechia | 16.64446 | 49.36304
Bruntál | N/A | Czechia | 17.4647 | 49.98844
Břeclav | N/A | Czechia | 16.88203 | 48.75897
Hodonín | N/A | Czechia | 17.13244 | 48.84893
Ostrava - Belsky Les | N/A | Czechia | N/A | N/A
Pilsen | N/A | Czechia | 13.37759 | 49.74747
Prague | N/A | Czechia | 14.42076 | 50.0880... | 596 | 2 | 0.003356 | 1 | NCT00680745 | 1COMPLETED | 2010-05-01 | 2008-04-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000921 |
[
4
] | 2,186 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | true | 1FEMALE | true | The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women. | null | Vasomotor Symptoms | Menopause Hot Flush Hot Flash Desvenlafaxine succinate Sustained Release | null | 2 | arm 1: desvenlafaxine succinate (DVS) SR arm 2: Placebo | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days. intervention 2: Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo ta... | intervention 1: desvenlafaxine succinate (DVS) SR intervention 2: Placebo | 121 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Mobile | Alabama | United States | -88.04305 | 30.69436
Montgomery | Alabama | United States | -86.29997 | 32.36681
Glendale | Arizona | United States | -112.18599 | 33.53865
Peoria | Arizona | United States | -112.23738 | 33.5806
Tucson | Arizona | United Sta... | 2,118 | 123 | 0.058074 | 1 | NCT00683800 | 1COMPLETED | 2010-05-01 | 2008-06-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4 | 106 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04889 |
[
4
] | 1,472 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG) + Ribavirin (RBV) (weight-based dosing \[WBD\]) in previously untreated adult participants with chronic hepatitis C (CHC) genotype 1. It is hypothesized that the addition of a third active anti- Hepatitis C Virus (anti-HCV) dru... | Participants from Cohort I and Cohort II are assigned (randomized) to one of three study arms, all of which have a 4-week lead-in period with (PEG + RBV).
1. Control arm, participants are treated with (PEG + RBV + placebo) for 44 weeks after the lead-in.
2. Experimental arm with Response Guided Therapy (RGT)
In th... | Hepatitis C, Chronic | null | 3 | arm 1: PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing \[WBD\]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up. arm 2: PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + ... | [
2,
0,
0
] | 4 | [
2,
0,
0,
0
] | intervention 1: Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC) intervention 2: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID). intervention 3: Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID). intervent... | intervention 1: Peginterferon alfa-2b (PEG) intervention 2: Ribavirin (RBV) intervention 3: Placebo intervention 4: Boceprevir | 0 | null | 1,097 | 2 | 0.001823 | 1 | NCT00705432 | 1COMPLETED | 2010-05-01 | 2008-08-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0005 | |
[
3
] | 167 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV). | null | HIV | Combination Therapy | null | 2 | arm 1: Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily arm 2: Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily | [
0,
1
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: Capsules, Oral, 300 mg, twice daily, 96 weeks intervention 2: Tablet, Oral, 400 mg, twice daily, 96 weeks intervention 3: Capsules, Oral, 300 mg, once daily, 96 weeks intervention 4: Capsules, Oral, 100 mg, once daily, 96 weeks intervention 5: Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once da... | intervention 1: Atazanavir intervention 2: Raltegravir intervention 3: Atazanavir intervention 4: Ritonavir intervention 5: Tenofovir/Emtricitabine | 16 | Phoenix | Arizona | United States | -112.07404 | 33.44838
New Haven | Connecticut | United States | -72.92816 | 41.30815
Washington D.C. | District of Columbia | United States | -77.03637 | 38.89511
Orlando | Florida | United States | -81.37924 | 28.53834
New York | New York | United States | -74.00597 | 40.71427
Cinci... | 93 | 1 | 0.010753 | 1 | NCT00768989 | 6TERMINATED | 2010-05-01 | 2008-11-01 | Bristol-Myers Squibb | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001901 |
[
4
] | 1,093 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety... | null | Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Metformin Dapagliflozin Hypoglycemic Agents Pharmacologic Actions Physiological Effects of Drugs | null | 3 | arm 1: Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks
Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks arm 2: Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.
Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks. arm 3: Metformin XR: Tablets, Oral... | [
0,
0,
1
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: Tablets, Oral, 10 mg, once daily, 24 weeks intervention 2: Tablets, Oral, up to 2000 mg, once daily, 24 weeks intervention 3: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks intervention 4: Tablets intervention 5: Tablets | intervention 1: Dapagliflozin intervention 2: Metformin XR intervention 3: Metformin XR intervention 4: dapagliflozin matching Placebo intervention 5: metformin HCl Modified Release matching Placebo | 123 | Ozark | Alabama | United States | -85.64049 | 31.45906
Tempe | Arizona | United States | -111.90931 | 33.41477
Tempe | Arizona | United States | -111.90931 | 33.41477
Concord | California | United States | -122.03107 | 37.97798
Encinitas | California | United States | -117.29198 | 33.03699
Fountain Valley | California ... | 638 | 3 | 0.004702 | 1 | NCT00859898 | 1COMPLETED | 2010-05-01 | 2009-04-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0016 |
[
3
] | 39 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study will evaluate the efficacy and safety of intravenous MK2578, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving erythropoietin stimulating agents. | This study consists of a 12-week base study (MK2578-003-AM03) and an optional 40-week extension study (MK2578-003-EXT12). Participants who complete 12 weeks of treatment in the base study will enter the extension on the most recent dose administered in the base study or a newly adjusted dose, if adjustment is required ... | Anemia Chronic Kidney Disease | Anemia associated with chronic kidney disease (CKD) Hemodialysis | null | 6 | arm 1: Participants were randomized to receive treatment every week (QW). arm 2: Participants were randomized to receive treatment QM. arm 3: Participants were randomized to receive treatment QW. arm 4: Participants were randomized to receive treatment QM. arm 5: Participants were randomized to receive treatment QW. ar... | [
0,
0,
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort. interve... | intervention 1: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline intervention 2: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline intervention 3: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline | 0 | null | 39 | 1 | 0.025641 | 1 | NCT00924781 | 6TERMINATED | 2010-05-01 | 2009-06-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.004541 |
[
3
] | 7 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study will define an effective starting dose for subcutaneous administration of MK2578 to correct anemia in erythropoiesis-stimulating agent (ESA)-naive patients with chronic kidney disease (CKD) who are not on dialysis while evaluating its safety. | null | Anemia Chronic Kidney Disease | Anemia | null | 4 | arm 1: MK2578 arm 2: MK2578 arm 3: MK2578 arm 4: darbepoetin alfa | [
0,
0,
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: MK2578 1.0 mcg/kg/month intervention 2: MK2578 2.0 mcg/kg/month intervention 3: MK2578 3.6 mcg/kg/month intervention 4: darbepoetin alfa | intervention 1: MK2578 intervention 2: MK2578 intervention 3: MK2578 intervention 4: Comparator: darbepoetin alfa | 0 | null | 7 | 1 | 0.142857 | 1 | NCT00968617 | 6TERMINATED | 2010-05-01 | 2009-11-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02568 |
[
4
] | 548 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This trial is conducted in Europe, Oceania, and the United States of America (USA).
The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart in patients with type 1 diabetes (main period) followed by the extension period comparing t... | null | Diabetes Diabetes Mellitus, Type 1 | null | 2 | arm 1: None arm 2: None | [
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted. intervention 2: Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted. intervention 3: Injected subcutaneously (under the skin) at the remaining meals. Dose was i... | intervention 1: insulin degludec/insulin aspart intervention 2: insulin detemir intervention 3: insulin aspart intervention 4: insulin aspart | 81 | La Mesa | California | United States | -117.02308 | 32.76783
Lancaster | California | United States | -118.13674 | 34.69804
Mission Hills | California | United States | -120.43683 | 34.68609
North Hollywood | California | United States | -118.37897 | 34.17223
Salinas | California | United States | -121.6555 | 36.67774
... | 542 | 1 | 0.001845 | 1 | NCT00978627 | 1COMPLETED | 2010-05-01 | 2009-08-01 | Novo Nordisk A/S | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000326 | |
[
3
] | 57 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | true | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery.
PURPOSE: Phase I/II trial to study the effectiveness of combination ... | OBJECTIVES:
* Determine the 5-year freedom from prostate-specific antigen (PSA) recurrence in patients treated with this regimen.
* Define the maximum tolerated dose of neoadjuvant docetaxel and mitoxantrone followed by prostatectomy in patients with high-risk localized prostate cancer. (Phase I completed as of 2/15/0... | Prostate Cancer | adenocarcinoma of the prostate stage II prostate cancer stage III prostate cancer | null | 1 | arm 1: Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg... | [
0
] | 3 | [
0,
0,
3
] | intervention 1: 35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule. intervention 2: Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly ... | intervention 1: docetaxel intervention 2: mitoxantrone hydrochloride intervention 3: conventional surgery | 2 | Portland | Oregon | United States | -122.67621 | 45.52345
Portland | Oregon | United States | -122.67621 | 45.52345 | 57 | 0 | 0 | 0 | NCT00017563 | 1COMPLETED | 2010-05-01 | 2000-09-01 | OHSU Knight Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 57 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating patients with recurrent glioma. | PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of BMS-247550 when administered to adults with recurrent malignant gliomas, receiving (Group A) or not receiving (Group B) anticonvulsants known to be metabolized by the P450 hepatic enzyme complex.
II. To describe the pharmacokinetics of this route of ad... | Adult Anaplastic Astrocytoma Adult Giant Cell Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor | null | 3 | arm 1: Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined ... | [
0,
0,
0
] | 3 | [
0,
10,
0
] | intervention 1: Given IV intervention 2: Correlative studies intervention 3: Drugs that induce hepatic Metabolic enzymes | intervention 1: ixabepilone intervention 2: pharmacological study intervention 3: Anticonvulsant | 5 | Atlanta | Georgia | United States | -84.38798 | 33.749
Baltimore | Maryland | United States | -76.61219 | 39.29038
Boston | Massachusetts | United States | -71.05977 | 42.35843
Winston-Salem | North Carolina | United States | -80.24422 | 36.09986
Cleveland | Ohio | United States | -81.69541 | 41.4995 | 57 | 0 | 0 | 0 | NCT00045708 | 1COMPLETED | 2010-05-01 | 2002-10-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 18 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX) in treating ulcerative colitis and examine the drug's effect on the immune system. People with ulcerative colitis have increased amounts of inflammatory chemicals (cytokines) made by immune cells in the lining of the colon. Stu... | The purpose of this pilot study is to evaluate the immunologic and clinical response to type I interferon administered to patients with ulcerative colitis. Ulcerative colitis (UC) is a chronic, relapsing inflammation of the colonic mucosa with major symptoms of diarrhea, hematochezia, abdominal pain, and an accompanyin... | Ulcerative Colitis | Lymphocyte Monocyte Inflammation Th2 Colonoscopy Ulcerative Colitis | null | 1 | arm 1: Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks | [
0
] | 1 | [
0
] | intervention 1: 30µg IM every week for 12 weeks | intervention 1: AVONEX | 1 | Bethesda | Maryland | United States | -77.10026 | 38.98067 | 16 | 0 | 0 | 0 | NCT00048347 | 1COMPLETED | 2010-05-01 | 2002-10-01 | National Institute of Allergy and Infectious Diseases (NIAID) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 138 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in patients who have had positive lymph nodes, and in patients who have had surgery for metastat... | Human leukocyte antigens (HLA-A)\*0201 positive patients at high risk for recurrence of melanoma, or completely resected metastatic melanoma will receive immunization with peptides representing human leukocyte antigen (HLA)-restricted T cell epitopes of the melanoma antigen recognized by T-cells (MART-1) or glycoprotei... | Melanoma | Adjuvant Therapy MART-1 Peptides GP100 Peptide Immunologic Response Melanoma | null | 8 | arm 1: melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I). arm 2: High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA) arm 3: 27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide e... | [
0,
0,
0,
0,
0,
0,
0,
0
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: None intervention 2: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses). intervention 3: None intervention 4: None intervention 5: None intervention 6: None | intervention 1: Glycoprotein 100 (GP100): 209-217 (210M) intervention 2: Interleukin-2 (IL-2) intervention 3: Montanide ISA 51 intervention 4: Melanoma antigen recognized by T-cells (MART)-1: 27-35 intervention 5: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1 intervention 6: melanoma antigen recognized b... | 1 | Bethesda | Maryland | United States | -77.10026 | 38.98067 | 138 | 0 | 0 | 0 | NCT00059475 | 1COMPLETED | 2010-05-01 | 2003-04-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 56 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | This phase II trial is studying the side effects of giving erlotinib together with carboplatin and paclitaxel and to see how well it works in treating patients with stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such as erlotinib may interfere with the growth of tumor ... | PRIMARY OBJECTIVES:
I. To establish whether the addition of OSI-774 (Tarceva) to the combination of paclitaxel and carboplatin encourages pathologic complete response (pCR) rates in patients with Stage III optimally cytoreduced (stratum 1) and Stage III suboptimally cytoreduced or Stage IV (stratum 2) ovarian, primary... | Brenner Tumor Fallopian Tube Cancer Ovarian Clear Cell Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Ovarian Undifferentiated Adenocarcinoma Stage III Ovarian Epithelial Cancer Stage IV Ovarian Epithelial Cancer | null | 1 | arm 1: Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Given IV intervention 2: Given IV intervention 3: Given PO | intervention 1: paclitaxel intervention 2: carboplatin intervention 3: erlotinib | 1 | The Bronx | New York | United States | -73.86641 | 40.84985 | 56 | 0 | 0 | 0 | NCT00059787 | 1COMPLETED | 2010-05-01 | 2003-04-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 1,571 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (P... | In developed countries, standard effective antiretroviral (ARV) therapy for treatment-naive HIV infected people includes three-drug combinations of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). However, direct c... | HIV Infections | Treatment Naive Adherence Drug Resistance Treatment Failure | null | 3 | arm 1: ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz arm 2: ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine arm 3: TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz | [
0,
0,
0
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: 400 mg taken orally daily intervention 2: 400 mg taken orally daily intervention 3: 600 mg taken orally daily intervention 4: 200 mg taken orally daily intervention 5: 200 mg/300 mg taken orally once daily intervention 6: 150 mg/300 mg taken orally twice daily | intervention 1: Atazanavir intervention 2: Didanosine (enteric-coated) intervention 3: Efavirenz intervention 4: Emtricitabine intervention 5: Emtricitabine/Tenofovir disoproxil fumarate intervention 6: Lamivudine/Zidovudine | 42 | Los Angeles | California | United States | -118.24368 | 34.05223
Los Angeles | California | United States | -118.24368 | 34.05223
Torrance | California | United States | -118.34063 | 33.83585
Denver | Colorado | United States | -104.9847 | 39.73915
Honolulu | Hawaii | United States | -157.85833 | 21.30694
Chicago | Ill... | 1,571 | 0 | 0 | 0 | NCT00084136 | 1COMPLETED | 2010-05-01 | 2005-05-01 | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 5NETWORK | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 25 | RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | true | RATIONALE: Calcitriol and dexamethasone may slow the growth of prostate cancer cells.
PURPOSE: This randomized phase II trial is studying how well giving calcitriol together with dexamethasone before radical prostatectomy works in treating patients with localized stage II or stage III adenocarcinoma (cancer) of the pr... | OBJECTIVES:
* Determine the effect of calcitriol and dexamethasone before radical prostatectomy on tumor vessel density in patients with localized adenocarcinoma of the prostate.
* Determine the effect of this regimen on the extent of prostatic intraepithelial neoplasia in these patients.
* Determine the effect of thi... | Prostate Cancer | adenocarcinoma of the prostate stage II prostate cancer stage III prostate cancer | null | 4 | arm 1: Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery. arm 2: No study drugs before surgery. arm 3: Patients receive oral dexamethasone once daily on days 1-4. arm 4: Patients receive oral calcitriol once daily on days 2-4. | [
0,
0,
0,
0
] | 3 | [
7,
0,
10
] | intervention 1: Given orally intervention 2: Given orally intervention 3: No intervention before surgery | intervention 1: calcitriol intervention 2: dexamethasone intervention 3: clinical observation | 1 | Buffalo | New York | United States | -78.87837 | 42.88645 | 25 | 0 | 0 | 0 | NCT00084864 | 6TERMINATED | 2010-05-01 | 2002-09-01 | Roswell Park Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 17 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. | PRIMARY OBJECTIVES:
I. To assess the efficacy (response rate and stable disease rate) of Bay 439006 given to patients with advanced or metastatic urothelial cancer.
II. To assess the toxicity, time to progression and response duration of Bay 439006 given to patients with advanced or metastatic urothelial cancer.
III... | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter Recurrent Bladder Cancer Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Regional Transitional Cell Cancer of the Renal Pelvis and Ureter Stage III Bladder Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder | null | 1 | arm 1: Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. | [
0
] | 2 | [
0,
10
] | intervention 1: Given orally 400mg orally twice daily intervention 2: Correlative studies | intervention 1: sorafenib tosylate intervention 2: laboratory biomarker analysis | 1 | Toronto | Ontario | Canada | -79.39864 | 43.70643 | 17 | 0 | 0 | 0 | NCT00112671 | 1COMPLETED | 2010-05-01 | 2005-04-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 40 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cispla... | Erlotinib and bevacizumab, novel biologics, offer a new regimen for the treatment of ovarian cancer in women who are refractory to standard drug regimens. Because bevacizumab is an anti-angiogenesis drug and erlotinib is an EGFR receptor inhibitor their combination would lead to the inhibition of multiple signal transd... | Ovarian Neoplasms | advanced ovarian cancer refractory ovarian cancer primary peritoneal cancer | null | 1 | arm 1: None | [
0
] | 2 | [
0,
0
] | intervention 1: 10mg/kg every two weeks IV-bevacizumab intervention 2: 150mg daily by mouth-erlotinib | intervention 1: bevacizumab intervention 2: erlotinib | 1 | Tucson | Arizona | United States | -110.92648 | 32.22174 | 40 | 0 | 0 | 0 | NCT00130520 | 1COMPLETED | 2010-05-01 | 2005-06-01 | University of Arizona | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 8 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics. | Schizophrenia is a devastating brain disorder. Most people with schizophrenia have difficulty filtering out unimportant auditory information. They have an inability to appropriately inhibit, or gate, sensory information that enters the ear. Standard treatments do not address this problem. When the drug ondansetron is t... | Schizophrenia | Schizophrenia Ondansetron P50 sensory gating Evoked potentials 5-HT3 receptors Atypical antipsychotics | null | 2 | arm 1: Participants will take ondansetron then placebo plus an atypical antipsychotic drug arm 2: Participants will take placebo then ondansetron plus an atypical antipsychotic drug | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period. intervention 2: Participants will take placebo daily for the f... | intervention 1: Ondansetron followed by placebo intervention 2: Placebo followed by Ondansetron | 1 | Denver | Colorado | United States | -104.9847 | 39.73915 | 0 | 0 | 0 | 0 | NCT00149734 | 1COMPLETED | 2010-05-01 | 2005-01-01 | University of Colorado, Denver | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 41 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease. | Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman line four times daily for 4 days, Cyclophosphamide intravenously via the Hickman line once a day for 4 days, and Anti-Thymocyte Globulin IV via the Hickman line twice daily for three days before the transplant. These three drugs... | Mucopolysaccharidosis I Mucopolysaccharidosis VI Mannosidosis Mucolipidosis Type II (I-cell Disease) | stem cell transplant storage disease errors of metabolism | null | 1 | arm 1: All patients treated with chemotherapy and transplantation. | [
0
] | 2 | [
3,
0
] | intervention 1: The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e.,... | intervention 1: Stem Cell Transplant intervention 2: Busulfan, Cyclophosphamide, ATG | 1 | Minneapolis | Minnesota | United States | -93.26384 | 44.97997 | 41 | 0 | 0 | 0 | NCT00176917 | 1COMPLETED | 2010-05-01 | 1999-05-01 | Masonic Cancer Center, University of Minnesota | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 20 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | null | This study is for patients with advanced ovarian cancer that has reappeared after treatment with conventional therapy. The purpose of this study is to determine if the combination of docetaxel and gemcitabine will be effective in reducing or eliminating the tumor(s) in patients with ovarian cancer.
Docetaxel is approv... | Primary Objective:
1\. To determine the response rate, time to progression and survival (secondary) of the combination of docetaxel and gemcitabine administered on a weekly basis to patients with platinum-resistant ovarian cancer
Secondary Objective:
1. To determine the toxicity of this combination regimen in patien... | Ovarian Carcinoma Peritoneal Neoplasms | Primary Peritoneal | null | 1 | arm 1: Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks. | [
0
] | 1 | [
0
] | intervention 1: Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle. | intervention 1: Docetaxel and Gemcitabine | 1 | Los Angeles | California | United States | -118.24368 | 34.05223 | 20 | 0 | 0 | 0 | NCT00183794 | 1COMPLETED | 2010-05-01 | 2002-11-01 | University of Southern California | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 17 | RANDOMIZED | CROSSOVER | 2DIAGNOSTIC | 0NONE | false | 0ALL | false | Treatment with growth hormone (GH; a hormone made by the body that stimulates growth) has been shown to be helpful in treating children with chronic kidney disease who fail to grow. The amount of growth that is seen in children treated with growth hormone varies widely for unknown reasons. Growth hormone works by produ... | The study will involve 30 children with chronic kidney disease and failure to grow. The study will last for 14 months. There will be a screening clinic visit if the child qualifies for the study, Week -8. Each clinic visit will include, getting a medical history, a physical exam, and a blood test. Also an x-ray of the ... | Kidney Failure, Chronic Growth Hormone Deficiency | Short stature children kidney failure, chronic Growth | null | 2 | arm 1: This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 day... | [
1,
1
] | 1 | [
0
] | intervention 1: Nutropin AQ | intervention 1: Nutropin AQ | 8 | Loma Linda | California | United States | -117.26115 | 34.04835
Los Angeles | California | United States | -118.24368 | 34.05223
Stanford | California | United States | -122.16608 | 37.42411
Portland | Oregon | United States | -122.67621 | 45.52345
Portland | Oregon | United States | -122.67621 | 45.52345
Houston | Tex... | 17 | 0 | 0 | 0 | NCT00212758 | 1COMPLETED | 2010-05-01 | 2005-01-01 | Oregon Health and Science University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 111 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | Currently, no effective drug treatment exists for cocaine dependence. Glutamate levels are disrupted with long-term cocaine use. N-acetyl cysteine (NAC) is a drug that is metabolized by the body to form cysteine, an active compound that normalizes glutamate levels. The purpose of this study is to determine the safety a... | Currently, no effective pharmacological treatment exists for cocaine dependence. Long-term use of cocaine disrupts normal glutamate levels. If addicts stop using cocaine, glutamate levels drop, which encourages addicts to continue seeking the drug. NAC is a drug that increases intracellular cysteine levels, which in tu... | Cocaine Dependence | Cocaine Dependence | null | 3 | arm 1: 1200mg N-Acetylcysteine arm 2: 2400mg N-Acetylcysteine arm 3: Matching Placebo | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: 1200mg N-Acetylcysteine intervention 2: 2400mg N-Acetylcysteine intervention 3: Matching Placebo | intervention 1: N-Acetylcysteine intervention 2: N-Acetylcysteine intervention 3: Matching Placebo | 1 | Charleston | South Carolina | United States | -79.93275 | 32.77632 | 111 | 0 | 0 | 0 | NCT00218491 | 1COMPLETED | 2010-05-01 | 2005-11-01 | Medical University of South Carolina | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 525 | RANDOMIZED | PARALLEL | 1PREVENTION | 0NONE | false | 0ALL | true | PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER.
The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (... | BACKGROUND:
The study is based on the premise that a community-based participatory research partnership model, using a team of an advanced practice nurse case manager, community health worker (CHW), and physician can be translated into urban community clinics and improve the quality of care and reduce disparities in c... | Cardiovascular Diseases Heart Diseases Coronary Disease Diabetes Mellitus Atherosclerosis Cerebral Arteriosclerosis Hypertension | null | 2 | arm 1: The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration wit... | [
1,
1
] | 4 | [
5,
0,
0,
0
] | intervention 1: Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise intervention 2: Aspirin 81 mg q day intervention 3: Oral medication intervention 4: Oral medications, received 1-2 times per day | intervention 1: Lifestyle Changes intervention 2: Antiplatelet Agents intervention 3: Beta Blocker intervention 4: ACE Inhibitors | 1 | Baltimore | Maryland | United States | -76.61219 | 39.29038 | 525 | 0 | 0 | 0 | NCT00241904 | 1COMPLETED | 2010-05-01 | 2006-05-01 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 137 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purposes of this study are:
1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and
2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance. | Individuals new to methadone maintenance will be asked to participate in this 6-month, double-blind, randomized control trial. All participants will complete a baseline interview, a medical screening and follow-up interviews at 1, 3 and 6-months post-baseline. These interviews take approximately 60 minutes, and survey ... | Poor Quality Sleep Opiate Addiction | sleep quality methadone substance use | null | 2 | arm 1: 50-150mg (50mg capsules) at bedtime for 90 days arm 2: 1-3 capsules at bedtime for 90 days | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 50 mg 1-3 capsules at bedtime for 3 months intervention 2: 1-3 at bedtime | intervention 1: Trazodone intervention 2: Placebo | 1 | Providence | Rhode Island | United States | -71.41283 | 41.82399 | 137 | 0 | 0 | 0 | NCT00253890 | 1COMPLETED | 2010-05-01 | 2005-10-01 | Butler Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 104 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study will evaluate the immunization effects of a vaccine for patients who are at risk for recurrence of their skin cancer. That is, the risk of cancer is higher if melanoma has invaded deep into the skin or lymph nodes. Currently, the only therapy that the U.S. Food and Drug Administration (FDA) has approved for ... | Background:
A previous clinical trial has been conducted in the Surgery Branch National Cancer Institute (NCI) in which gp100 immunizations have been administered to patients with melanoma in the adjuvant setting. In this prior protocol, the peptide emulsified in Incomplete Freund's Adjuvant was administered subcutane... | High-Risk Melanoma | Disease Free Survival gp 100:209-217 (210m) Immunologic Response Adjuvant Therapy Cutaneous Melanoma Melanoma | null | 6 | arm 1: gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks). arm 2: gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one eve... | [
0,
0,
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days | intervention 1: gp100:209-217 (210M) intervention 2: Montanide ISA-51 intervention 3: Imiquimod | 1 | Bethesda | Maryland | United States | -77.10026 | 38.98067 | 104 | 0 | 0 | 0 | NCT00273910 | 1COMPLETED | 2010-05-01 | 2006-01-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 380 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 2MALE | true | The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia. | null | Benign Prostatic Hyperplasia | null | 4 | arm 1: Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1. arm 2: Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1. arm 3: Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1. arm 4: Placebo (Normal Saline) transperineal or transrectal injec... | [
0,
0,
0,
2
] | 2 | [
2,
0
] | intervention 1: Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1. intervention 2: Normal Saline (Placebo) transperineal or transrectal injection on Day 1. | intervention 1: botulinum toxin Type A intervention 2: normal saline | 11 | Murdoch | N/A | Australia | 115.83757 | -32.06987
Vienna | N/A | Austria | 16.37208 | 48.20849
Victoria | British Columbia | Canada | -123.35155 | 48.4359
Olomouc | N/A | Czechia | 17.25175 | 49.59552
Paris | N/A | France | 2.3488 | 48.85341
Braunschweig | N/A | Germany | 10.52673 | 52.26594
Perugia | N/A | Italy | 12.... | 373 | 0 | 0 | 0 | NCT00284518 | 1COMPLETED | 2010-05-01 | 2005-12-01 | Allergan | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 57 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension study is designed to e... | null | Hereditary Angioedema | C1 Inhibitor Hereditary angioedema Acute HAE attack | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv | intervention 1: C1 Esterase Inhibitor | 14 | Weston | Florida | United States | -80.39977 | 26.10037
Atlanta | Georgia | United States | -84.38798 | 33.749
Idaho Falls | Idaho | United States | -112.03414 | 43.46658
Chicago | Illinois | United States | -87.65005 | 41.85003
Shreveport | Louisiana | United States | -93.75018 | 32.52515
Boston | Massachusetts | Unit... | 57 | 0 | 0 | 0 | NCT00292981 | 1COMPLETED | 2010-05-01 | 2005-08-01 | CSL Behring | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 50 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is based on the induction of complete responses. Randomized tr... | null | Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia Relapsed Leukemia | clofarabine acute leukemia ALL AML clolar CLO218 | null | 1 | arm 1: Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m\^2, etoposide dosage from 75-100 mg/m\^2, cyclophosphamide dosage from 340-440 mg/m\^2.
Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m\^2, etoposide 100 mg/m\^2 and cyclophosphamide ... | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods. intervention 2: Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion da... | intervention 1: clofarabine intervention 2: Etoposide intervention 3: Cyclophosphamide | 13 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Los Angeles | California | United States | -118.24368 | 34.05223
San Diego | California | United States | -117.16472 | 32.71571
Hartford | Connecticut | United States | -72.68509 | 41.76371
Chicago | Illinois | United States | -87.65005 | 41.85003
Indianapolis... | 75 | 0 | 0 | 0 | NCT00315705 | 1COMPLETED | 2010-05-01 | 2006-03-01 | Genzyme, a Sanofi Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 60 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses ... | OBJECTIVES:
Primary
* Explore the activity of cisplatin, fluorouracil, gefitinib, and hyperfractionated radiotherapy, in terms of 1-year survival and 1-year distant metastatic disease control, in patients with locally advanced squamous cell carcinoma of the head and neck.
Secondary
* Explore the activity of this re... | Head and Neck Cancer | stage III squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the hypopharynx stage III squamous cell carcinoma of the larynx stage IV squamous cell carcinoma of the larynx stage III squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the lip and oral cavity... | null | 1 | arm 1: None | [
0
] | 4 | [
0,
0,
0,
4
] | intervention 1: 20mg/m2/d IV continuous infusion x4 days intervention 2: 1000mg.m2/d IV continuous x 4 days intervention 3: 250mg/PO qd x 2 years intervention 4: 120cGy bid | intervention 1: cisplatin intervention 2: fluorouracil intervention 3: Iressa intervention 4: hyperfractionated radiation therapy | 1 | Cleveland | Ohio | United States | -81.69541 | 41.4995 | 60 | 0 | 0 | 0 | NCT00352105 | 1COMPLETED | 2010-05-01 | 2006-04-01 | David Adelstein | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 372 | RANDOMIZED | SINGLE_GROUP | 1PREVENTION | 3TRIPLE | false | 1FEMALE | true | This is a single center trial to compare the rate of surgical site infection (SSI) in normal (BMI equal to or less than 25; Control Group)) and overweight (BMI over 25) women who are undergoing breast cancer surgery. The overweight patients are further randomized into two groups; in one group patients receive prophylac... | CONTEXT Although breast surgery is regarded as clean surgery, the actual SSI rate is well above accepted range in various series. Retrospective studies showed BMI as one of the factors which may have caused increased SSI rate after breast cancer surgery. Yet, no prospective randomized study assessed the efficacy of che... | Breast Cancer | breast cancer breast surgery clean wound overweight prophylaxis antibiotics | null | 2 | arm 1: patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis arm 2: Patients who are BMI over 25 and do not receive antibiotic prophylaxis | [
1,
4
] | 1 | [
0
] | intervention 1: Ampicillin/Sulbactam 1 gr, once within onr hour before surgery | intervention 1: Ampicillin/Sulbactam | 1 | Istanbul | N/A | Turkey (Türkiye) | 28.94966 | 41.01384 | 372 | 0 | 0 | 0 | NCT00356148 | 1COMPLETED | 2010-05-01 | 2003-10-01 | Marmara University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 6 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This phase II trial is studying how well giving SGN-30 together with combination chemotherapy works in treating patients with newly diagnosed anaplastic large cell lymphoma. Monoclonal antibodies, such as SGN-30, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Other... | PRIMARY OBJECTIVES:
I. Determine the efficacy of monoclonal antibody SGN-30 in combination with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) in patients with newly diagnosed anaplastic large cell lymphoma (ALCL).
II. Determine the safety of combining monoclonal antibody SGN-30 with ... | Anaplastic Large Cell Lymphoma | non-Hodgkin's lymphoma NHL murine monoclonal antibody mAb SGN-30 CHOP Cyclophosphamide Doxorubicin Hydrochloride Vincristine Prednisone anaplastic large cell lymphoma Lymphoma Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoma, Large-Cell, Anaplastic Neoplasms by Histologic Type Neoplasms Lymphoproliferativ... | null | 1 | arm 1: Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.
SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophospha... | [
0
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: Given IV 750 mg/m\^2 day 1 intervention 2: Given 50 mg/m\^2 IV day 1 intervention 3: Given 1.4 mg/m\^2 IV intervention 4: 100 mg orally daily days 1 - 5 intervention 5: 12 mg/kg weekly IV over 2 hours once weekly for 3 weeks. | intervention 1: Cyclophosphamide intervention 2: Doxorubicin hydrochloride intervention 3: vincristine sulfate intervention 4: prednisone intervention 5: SGN-30 | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 6 | 0 | 0 | 0 | NCT00365274 | 6TERMINATED | 2010-05-01 | 2006-08-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 116 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.
This study will evaluate the efficacy of clofarabine in elderly patients with... | null | Acute Myelogenous Leukemia Acute Myeloid Leukemia | Acute myelogenous leukemia Acute myeloid leukemia newly Diagnosed AML Clofarabine CLASSIC II CLO243 | null | 1 | arm 1: Participants received an induction cycle of clofarabine 30 mg/m\^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day intravenous infusion for 5 consecutive days. | [
0
] | 1 | [
0
] | intervention 1: Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.
Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive day... | intervention 1: clofarabine | 20 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Tucson | Arizona | United States | -110.92648 | 32.22174
Los Angeles | California | United States | -118.24368 | 34.05223
San Diego | California | United States | -117.16472 | 32.71571
Denver | Colorado | United States | -104.9847 | 39.73915
Southington | Connec... | 112 | 0 | 0 | 0 | NCT00373529 | 1COMPLETED | 2010-05-01 | 2006-10-01 | Genzyme, a Sanofi Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 94 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The Johns Hopkins Department of Psychiatry is conducting a research study to examine the effectiveness of riluzole in treating the depressed phase of bipolar disorder. This outpatient treatment study of medication or placebo will last 9-12 weeks. The study includes medical and psychiatric evaluations as well as time-li... | The study will last 8 to 12 weeks and requires weekly visits. Participants will come to Johns Hopkins for a screening visit during which they will talk with a psychiatrist, answer questions about their mood and symptoms, have their blood drawn and have a brief physical exam. If they meet criteria for the study, any ant... | Bipolar Disorder | Bipolar Depression | null | 2 | arm 1: Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses ... | [
0,
2
] | 2 | [
0,
10
] | intervention 1: Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be... | intervention 1: Riluzole intervention 2: Placebo | 1 | Baltimore | Maryland | United States | -76.61219 | 39.29038 | 94 | 0 | 0 | 0 | NCT00376220 | 1COMPLETED | 2010-05-01 | 2004-05-01 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 49 | RANDOMIZED | CROSSOVER | 0TREATMENT | 3TRIPLE | false | 0ALL | true | The objective of this study is to determine MK-0677 increases IGF-1 in patients with end stage renal disease (ESRD) on hemodialysis. | With development and progression of chronic kidney disease (CKD) to end stage renal disease (ESRD), malnutrition becomes an increasingly severe problem. This is thought to occur from two mechanisms: decreased appetite secondary to uremia and development of a catabolic inflammatory milieu. Patients experience decreased ... | Chronic Kidney Disease End Stage Renal Disease | Chronic kidney disease End stage renal disease | null | 2 | arm 1: MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days. arm 2: MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days. | [
0,
0
] | 2 | [
0,
0
] | intervention 1: The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days. intervention 2: Placebo | intervention 1: MK-0677 intervention 2: Placebo | 1 | Charlottesville | Virginia | United States | -78.47668 | 38.02931 | 52 | 0 | 0 | 0 | NCT00395291 | 1COMPLETED | 2010-05-01 | 2006-08-01 | University of Virginia | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 72 | RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This Phase Ib/II, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and efficacy of dulanermin when combined with rituximab in subjects with follicular, CD20+, B-cell Non-Hodgkin's Lymphoma (NHL) that has progressed following a response of ≥ 6 months duration to a prior rituximab-conta... | null | Non-Hodgkin's Lymphoma | NHL Follicular NHL Rituxan Apo2L/TRAIL | null | 5 | arm 1: Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m\^2 weekly for up to eight doses. arm 2: Particip... | [
0,
0,
1,
0,
0
] | 2 | [
0,
0
] | intervention 1: Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle. intervention 2: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses. | intervention 1: Dulanermin intervention 2: Rituximab | 0 | null | 71 | 0 | 0 | 0 | NCT00400764 | 6TERMINATED | 2010-05-01 | 2006-06-01 | Genentech, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 38 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival. | Treatment with Carboplatin and gemcitabine is one of the most active combination therapies used for first-line therapy of NSCLC. The optimum schedule for administration of carboplatin and gemcitabine is currently unknown.
The addition of bevacizumab to another comparable platinum combination showed an overall survival... | Carcinoma, Non-Small-Cell Lung | Carcinoma, Non-Small-Cell Lung Gemcitabine Carboplatin Bevacizumab Biological therapy Drug therapy | null | 1 | arm 1: Patients treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of ... | [
0
] | 1 | [
0
] | intervention 1: Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks ... | intervention 1: Gemcitabine, Carboplatin, Bevacizumab | 2 | Minneapolis | Minnesota | United States | -93.26384 | 44.97997
Minneapolis | Minnesota | United States | -93.26384 | 44.97997 | 38 | 0 | 0 | 0 | NCT00400803 | 1COMPLETED | 2010-05-01 | 2007-03-01 | Masonic Cancer Center, University of Minnesota | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 70 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC). This study will be conducted in Asian patients who are classified as 'never smoker' since it is suggested that t... | null | Non-small Cell Lung Cancer | null | 2 | arm 1: Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity. arm 2: Pemetrexed 500 millig... | [
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: 500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity. intervention 2: 75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cyc... | intervention 1: Pemetrexed intervention 2: Cisplatin intervention 3: Gefitinib | 7 | Fujian | N/A | China | 106.12972 | 28.92651
Qingdao | N/A | China | 120.38042 | 36.06488
Shanghai | N/A | China | 121.45806 | 31.22222
Seoul | N/A | South Korea | 126.9784 | 37.566
Changhua | N/A | Taiwan | 120.5512 | 24.0692
Taipei | N/A | Taiwan | 121.52639 | 25.05306
Taoyuan District | N/A | Taiwan | 121.3187 | 24.9... | 70 | 0 | 0 | 0 | NCT00409006 | 1COMPLETED | 2010-05-01 | 2007-02-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 15 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | true | 0ALL | null | This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment.
Secondary objectives of this study are:
•-to evaluate if there is an improvement in disability levels foll... | Memantine is an FDA approved treatment which helps slow down the progression of Alzheimer's dementia.. It is felt that high glutamate levels associated with Alzheimer's dementia are toxic to neurons which ultimately die off causing the dementia process to continue. Memantine partially blocks the NMDA glutamate channels... | General Anxiety Disorder, Social Anxiety Disorder | Anxiety, SNRI, SSRI,GAD,SAD | null | 1 | arm 1: Memantine tablets 5-20mg/d flexible dose | [
0
] | 1 | [
0
] | intervention 1: 5mg tablets, 1-4 tabs by mouth per day | intervention 1: Namenda/Memantine | 1 | Syracuse | New York | United States | -76.14742 | 43.04812 | 15 | 0 | 0 | 0 | NCT00411398 | 1COMPLETED | 2010-05-01 | 2006-12-01 | State University of New York - Upstate Medical University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 11 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | false | Rapamune (generic name: Sirolimus®) is a drug that has been approved by the Food and Drug Administration (government) for use in patients receiving a kidney transplant to prevent the patient's body from rejecting the transplanted kidney. It has shown antitumor effects in the laboratory, but has not been approved at thi... | null | Breast Cancer | HER-2 positive breast cancer HER-2 positive breast cancer | null | 1 | arm 1: Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 ... | [
0
] | 2 | [
0,
0
] | intervention 1: oral rapamycin 6 mg daily intervention 2: Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8. | intervention 1: Rapamycin intervention 2: Trastuzumab | 2 | Bridgeport | Connecticut | United States | -73.18945 | 41.17923
New Haven | Connecticut | United States | -72.92816 | 41.30815 | 9 | 0 | 0 | 0 | NCT00411788 | 1COMPLETED | 2010-05-01 | 2006-12-01 | Yale University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 100 | NA | SINGLE_GROUP | 4SUPPORTIVE_CARE | 0NONE | false | 1FEMALE | false | This phase II trial is studying vitamin D deficiency, muscle pain, joint pain, and joint stiffness in postmenopausal women receiving letrozole for stage I-III breast cancer. Learning about vitamin D deficiency and muscle pain, joint pain, and joint stiffness in patients receiving letrozole for breast cancer may help do... | PRIMARY OBJECTIVES:
I. To assess the rate of vitamin D deficiency in breast cancer patients who experience myalgias, arthralgias and/or joint stiffness following initiation of adjuvant letrozole treatment.
SECONDARY OBJECTIVES:
I. To determine if there is a correlation between letrozole serum levels and the developm... | Arthralgia Musculoskeletal Complications Pain Recurrent Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer | null | 1 | arm 1: Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable to... | [
0
] | 9 | [
0,
7,
10,
7,
7,
0,
7,
3,
3
] | intervention 1: Given PO intervention 2: Given PO intervention 3: Optional correlative studies intervention 4: Given PO intervention 5: Given PO intervention 6: Given PO intervention 7: Given PO intervention 8: Ancillary studies intervention 9: Correlative studies | intervention 1: letrozole intervention 2: calcium carbonate intervention 3: laboratory biomarker analysis intervention 4: calcium citrate intervention 5: calcium glucarate intervention 6: calcium gluconate intervention 7: cholecalciferol intervention 8: assessment of therapy complications intervention 9: musculoskeleta... | 1 | Seattle | Washington | United States | -122.33207 | 47.60621 | 100 | 0 | 0 | 0 | NCT00416715 | 1COMPLETED | 2010-05-01 | 2006-10-01 | University of Washington | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 31 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | Chronic hemodialysis (CHD) patients display multiple metabolic abnormalities related to advanced uremia. Despite vigorous attempts to prevent these abnormalities and their consequences, most CHD patients suffer from a unique form of nutritional derangement, which can be termed as "uremic wasting". Several studies have ... | null | End Stage Renal Disease | inflammation end stage renal disease | null | 2 | arm 1: Interleukin-1 receptor antagonist arm 2: None | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks intervention 2: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks | intervention 1: kineret intervention 2: placebo | 1 | Nashville | Tennessee | United States | -86.78444 | 36.16589 | 14 | 0 | 0 | 0 | NCT00420290 | 1COMPLETED | 2010-05-01 | 2008-01-01 | Vanderbilt University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 81 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | true | The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) and topiramate in the treatment of cocaine dependence. Since both of these medications have independently shown promise in helping with cocaine abuse we are proposing that together they may be... | Specific Aim 1: To determine the efficacy of ER-MAS and topiramate in promoting cocaine abstinence among cocaine-dependent patients.
Primary Hypothesis: The proportion of participants achieving sustained cocaine abstinence (via urine toxicology) for three consecutive weeks during the study will be significantly greate... | Cocaine Dependence | Cocaine Adderall Topiramate ADHD | null | 2 | arm 1: Adderall-XR (60 mg/day) and Topiramate (300mg/day) arm 2: Placebo | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Adderall-XR 60mg/day and Topiramate 300mg/day intervention 2: Placebo | intervention 1: Adderall-XR and Topiramate intervention 2: Placebo | 1 | New York | New York | United States | -74.00597 | 40.71427 | 81 | 0 | 0 | 0 | NCT00421603 | 1COMPLETED | 2010-05-01 | 2007-02-01 | New York State Psychiatric Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 22 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 1FEMALE | false | The purpose of this study is to determine whether alkalized lidocaine instilled into the bladder is effective in the treatment of overactive bladder (OAB). | Existing first-line treatments for overactive bladder are limited by requirements for chronic dosing and associated systemic side effects. Small case series suggest that bladder instillation of lidocaine may be effective in downregulating the afferent neuronal activity of a sensitized bladder, leading to elevation of t... | Overactive Bladder | Administration, Intravesical Anesthetics, Local | null | 2 | arm 1: xylocaine arm 2: normal saline | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks intervention 2: normal saline | intervention 1: alkalinized xylocaine intervention 2: placebo | 2 | Evanston | Illinois | United States | -87.69006 | 42.04114
Park City | Illinois | United States | -87.88424 | 42.34836 | 18 | 0 | 0 | 0 | NCT00427648 | 6TERMINATED | 2010-05-01 | 2006-03-01 | Frank Tu | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 39 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV). All participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneously once weekly. Following 4... | null | Hepatitis B, Chronic | null | 1 | arm 1: Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks. | [
0
] | 1 | [
0
] | intervention 1: 180 mcg subcutaneously once per week for 48 weeks. | intervention 1: Peginterferon alfa-2a | 9 | Tallinn | N/A | Estonia | 24.75353 | 59.43696
Tallinn | N/A | Estonia | 24.75353 | 59.43696
Tartu | N/A | Estonia | 26.72509 | 58.38062
Riga | N/A | Latvia | 24.10589 | 56.946
Kaunas | N/A | Lithuania | 23.90961 | 54.90272
Kaunas | N/A | Lithuania | 23.90961 | 54.90272
Klaipėda | N/A | Lithuania | 21.13912 | 55.7068
Vi... | 39 | 0 | 0 | 0 | NCT00436163 | 1COMPLETED | 2010-05-01 | 2007-03-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 64 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of the study is to compare the effectiveness of a steroid injection to a placebo (inactive substance) in the treatment of lateral elbow pain, deQuervain's tendonitis, or base of the thumb carpometacarpal (CMC) arthritis. We are also trying to identify which personality factors and mindsets influence percept... | Pain at the origin of the extensor carpi radialis is an extremely common problem. Most patients are between 35 and 55 years of age. This problem has been referred to as tennis elbow, but fewer than 10% of patients with this problem play tennis, and it is not a common problem among professional tennis players. The probl... | Lateral Elbow Pain | lateral elbow pain tennis elbow pain psychology | null | 3 | arm 1: The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis. arm 2: None arm 3: The CMC Arthritis injection study was terminated due to difficulty wit... | [
1,
1,
1
] | 2 | [
0,
0
] | intervention 1: Injection without steroid intervention 2: Injection with steroid (dexamethasone) | intervention 1: Placebo Injection intervention 2: Steroid (dexamethasone) Injection | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 64 | 0 | 0 | 0 | NCT00438672 | 1COMPLETED | 2010-05-01 | 2003-04-01 | Massachusetts General Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 10 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 2MALE | false | This randomized phase II trial studies how well different doses of lycopene work in treating patients undergoing radical prostatectomy for prostate cancer. The use of lycopene, a substance found in tomatoes, may keep prostate cancer from growing or coming back after surgery. | PRIMARY OBJECTIVES:
I. Compare the differences in tissue concentrations of lycopene in patients with prostate cancer undergoing radical prostatectomy treated with different doses of neoadjuvant lycopene supplementation.
II. Compare the change in serum lycopene concentration from baseline and at 4-7 weeks in patients ... | Adenocarcinoma of the Prostate Stage I Prostate Cancer Stage II Prostate Cancer Stage III Prostate Cancer | null | 3 | arm 1: Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy. arm 2: Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy. arm 3: Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy. | [
2,
0,
0
] | 4 | [
10,
3,
10,
0
] | intervention 1: Given PO intervention 2: Undergo radical prostatectomy intervention 3: Correlative studies intervention 4: Given PO | intervention 1: placebo intervention 2: therapeutic conventional surgery intervention 3: laboratory biomarker analysis intervention 4: lycopene | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 10 | 0 | 0 | 0 | NCT00450749 | 1COMPLETED | 2010-05-01 | 2008-02-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 23 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will improve outcomes for this population. | Depression and alcohol use disorders contribute to a significant proportion of the burden of disease, in the United States and abroad. Patients who suffer from co-morbid depression and alcohol abuse/dependence have illnesses that are more severe, persistent and costly than people with either depression or an alcohol us... | Major Depressive Disorder Alcohol Abuse Alcohol Dependence | Major depressive disorder Alcoholism Alcohol abuse Alcohol dependence | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 4 | [
0,
0,
5,
0
] | intervention 1: Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks. intervention 2: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD. intervention 3: Based on the COMBINE stu... | intervention 1: acamprosate intervention 2: escitalopram intervention 3: Medical management intervention 4: Placebo | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 23 | 0 | 0 | 0 | NCT00452543 | 1COMPLETED | 2010-05-01 | 2007-03-01 | Massachusetts General Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 45 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy with porfimer sodium works in treating pati... | OBJECTIVES:
* Determine the efficacy of photodynamic therapy with porfimer sodium in patients with pre-malignant lesions, carcinoma in situ, select superficial squamous cell carcinoma of the oral cavity, oropharynx, or larynx, or condemned mucosa syndrome in the upper aerodigestive tract.
* Determine the safety of thi... | Head and Neck Cancer Precancerous/Nonmalignant Condition | recurrent squamous cell carcinoma of the lip and oral cavity stage II squamous cell carcinoma of the lip and oral cavity stage III squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the lip and oral cavity recurrent squamous cell carcinoma of the oropharynx stage II squamous cell car... | null | 1 | arm 1: None | [
0
] | 2 | [
0,
3
] | intervention 1: Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home. intervention 2: Laser Activation. The time of exposure and the power of the laser are compu... | intervention 1: Porfimer Sodium intervention 2: Photodynamic Therapy | 1 | Miami | Florida | United States | -80.19366 | 25.77427 | 45 | 0 | 0 | 0 | NCT00453336 | 1COMPLETED | 2010-05-01 | 2003-06-01 | University of Miami | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 25 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to compare the effects of two different combination therapies for high blood pressure on vascular health. | Hydrochlorothiazide (HCTZ) has been a popular choice for the treatment of hypertension mainly due to its efficacy in lowering blood pressure, safety, and cost-effectiveness. Similarly, angiotensin converting enzyme inhibitors (ACE-I), because of their neutral to positive impact on glycemic control, have been a popular ... | Abdominal Obesity Hypertension | null | 2 | arm 1: Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months. arm 2: Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and th... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectivel... | intervention 1: Carvedilol CR + Lisinopril intervention 2: Lisinopril + HCTZ | 1 | Saint Paul | Minnesota | United States | -93.09327 | 44.94441 | 25 | 0 | 0 | 0 | NCT00459056 | 1COMPLETED | 2010-05-01 | 2007-04-01 | St. Paul Heart Clinic | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 5 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 1FEMALE | false | The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal patients with hormone sensitive breast cancer. | null | Hormone-Sensitive Breast Cancer Breast Cancer | Neoadjuvant treatment | null | 2 | arm 1: brief exposure bevacizumab arm 2: brief exposure bevacizumab and letrozole | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Letrozole 2.5 mg po qd intervention 2: bevacizumab 10 mg/kg IV | intervention 1: Letrozole intervention 2: Bevacizumab | 1 | New Haven | Connecticut | United States | -72.92816 | 41.30815 | 5 | 0 | 0 | 0 | NCT00461773 | 6TERMINATED | 2010-05-01 | 2007-03-01 | Yale University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 3 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional transplantation regimen. | This study tests a tandem transplant approach that starts with transplantation of the participant's own hematopoietic (blood) cells, eg, autologous hematopoietic cell transplant (auto-HCT) as preparation for an subsequent matched-donor allogeneic HCT (allo-HCT).
Participants will be have progenitor cells (stem cells) ... | Lymphoma, B-cell Lymphoma, Non-Hodgkin Diffuse Large B-cell Lymphoma (DLBCL) Malignant Lymphoma, Non-Hodgkin | null | 1 | arm 1: Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as condit... | [
0
] | 15 | [
3,
3,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] | intervention 1: Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents intervention 2: Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgra... | intervention 1: Autologous hematopoietic stem cell transplantation (auto-HSCT) intervention 2: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) intervention 3: Total lymphoid irradiation (TLI) intervention 4: Rituximab intervention 5: Carmustine intervention 6: Etoposide intervention 7: Filgrastim interve... | 1 | Stanford | California | United States | -122.16608 | 37.42411 | 3 | 0 | 0 | 0 | NCT00482053 | 6TERMINATED | 2010-05-01 | 2006-10-01 | Stanford University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 27 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The goal of this clinical research study is to find out if CEP-701 can help control myelofibrosis (MF). The safety of CEP-701 will also be studied. | The Study Drug:
CEP-701 is designed to help prevent a certain type of molecule (called a mutated JAK2 receptor) that is found on myelofibrosis cells from sending continuous chemical signals that lead to the growth of cancer cells.
Study Treatment:
If you are found to be eligible to take part in this study, you will ... | Leukemia Myelofibrosis | CEP-701 Leukemia Myelofibrosis MF JAK2 Tyrosine Kinase Inhibitor Lestaurtinib Chronic Idiopathic Myelofibrosis CIMF | null | 1 | arm 1: 80 mg orally twice a day for 30 days | [
0
] | 1 | [
0
] | intervention 1: 80 mg orally twice a day for 30 days | intervention 1: CEP-701 | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 22 | 0 | 0 | 0 | NCT00494585 | 1COMPLETED | 2010-05-01 | 2007-06-01 | M.D. Anderson Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 6 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Systemic Sclerosis (Scleroderma) varies greatly in clinical manifestations, mode of presentation, and course. The natural history of this chronic autoimmune disease ranges from benign to fatal. Patients are classified into limited and diffuse scleroderma defined by the degree of skin involvement. Patients with limited ... | Study design
The study was an open-label, single-site trial of a single exposure to high-dose cyclophosphamide without stem cell rescue. Each patient was followed up by the same doctor to eliminate interobserver skin score variation. Baseline measurements included comprehensive laboratory studies that included complet... | Scleroderma | High Dose Cyclophosphamide Systemic Sclerosis Scleroderma immunoablation | null | 1 | arm 1: This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter . | [
0
] | 1 | [
0
] | intervention 1: Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day) | intervention 1: IV Cyclophosphamide | 0 | null | 6 | 0 | 0 | 0 | NCT00501995 | 1COMPLETED | 2010-05-01 | 2001-02-01 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 44 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer. | OBJECTIVES:
Primary
* To estimate the effect of erlotinib hydrochloride on expression of interleukin (IL)-1α in patients with estrogen receptor (ER-)-negative, EGFR-positive and IL-1α-positive breast cancer.
Secondary
* To estimate the effect of erlotinib hydrochloride on expression of nuclear NF-κB and amphireguli... | Breast Cancer | stage I breast cancer recurrent breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer | null | 1 | arm 1: Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity. | [
0
] | 6 | [
0,
10,
10,
3,
3,
3
] | intervention 1: Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity. intervention 2: Assessed at the time of the initial biopsy and at the time of surgery. interventio... | intervention 1: erlotinib hydrochloride intervention 2: immunohistochemistry staining method intervention 3: laboratory biomarker analysis intervention 4: biopsy intervention 5: conventional surgery intervention 6: neoadjuvant therapy | 1 | Detroit | Michigan | United States | -83.04575 | 42.33143 | 0 | 0 | 0 | 0 | NCT00503841 | 6TERMINATED | 2010-05-01 | 2007-12-01 | Barbara Ann Karmanos Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 16 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | false | Primary Objectives:
* To determine the objective response rate of Letrozole when administered to patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary , fallopian tube or peritoneum.
* To determine the time to tumor progression of patients with advanced or recurrent borde... | Letrozole is an anticancer hormone that is FDA approved for use in patients with advanced breast cancer.
Before you can be enrolled in this study, you must go through some screening tests to make sure you are eligible. The screening tests include a complete medical history and physical exam, including measurement of y... | Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer | Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer Letrozole Femara | null | 1 | arm 1: 2.5 mg by mouth (PO) daily | [
0
] | 1 | [
0
] | intervention 1: 2.5 mg PO Once Daily | intervention 1: Letrozole | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 16 | 0 | 0 | 0 | NCT00505661 | 6TERMINATED | 2010-05-01 | 2003-09-01 | M.D. Anderson Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 54 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | true | 0ALL | false | To determine the effects of policosanol on the cholesterol profile. | The primary objectives of this study are to determine the changes in the lipid profile \[LDL-C, HDL-C, triglycerides, total cholesterol\] and the emerging risk factor, Lp(a), when policosanol is added to statin therapy. Additionally, one more primary objective is to evaluate the safety of the combination regimen. | High Cholesterol | null | 3 | arm 1: Policosanol 20mg daily arm 2: None arm 3: Policosanol 20mg daily Plus Statin Therapy Already In Use | [
1,
2,
1
] | 3 | [
0,
10,
0
] | intervention 1: Policosanol 20 mg daily intervention 2: Placebo daily intervention 3: Policosanol 20 mg daily Statin Therapy | intervention 1: Policosanol intervention 2: Placebo intervention 3: Policosanol Plus Already In Use Statin Therapy | 1 | Kansas City | Kansas | United States | -94.62746 | 39.11417 | 54 | 0 | 0 | 0 | NCT00510809 | 1COMPLETED | 2010-05-01 | 2007-07-01 | James Backes, PharmD | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3,
4
] | 10 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The investigators hypothesize that the anabolic effects of Genotropin (somatropin) will improve the height and weight of children with inflammatory based chronic illness who have failed to grow despite receiving adequate nutrition. The investigators will test the hypothesis by treating 32 chronically ill children (16 J... | 1. To determine the effect of GenotropinTM on height, height velocity, body weight and lean body mass. Growth records from previous years will be assessed to determine growth velocity and weight gain. We will measure height and weight during the study using a standardized stadiometer and scale. These parameters will be... | Arthritis, Juvenile Rheumatoid Crohn Disease | growth hormone short stature growth failure chronic illness | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages. | intervention 1: somatropin [rDNA origin] for injection | 1 | Columbus | Ohio | United States | -82.99879 | 39.96118 | 0 | 0 | 0 | 0 | NCT00511329 | 6TERMINATED | 2010-05-01 | 2007-08-01 | Nationwide Children's Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 140 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 2MALE | true | The purpose of this placebo-controlled study is to determine if testosterone replacement therapy, administered by transdermal gel, can improve the response to sildenafil (Viagra R) treatment in men who have erectile dysfunction (ED) and low testosterone levels. | This is a double-blind, placebo-controlled, parallel-group, randomized clinical trial in men, 40-70 years of age, who present with mild to moderate erectile dysfunction and have androgen deficiency defined as serum total testosterone level below 300 ng/dL, measured by liquid chromatography tandem mass spectrometry, LC-... | Erectile Dysfunction Testosterone Deficiency Diabetes | testosterone erectile dysfunction sildenafil | null | 2 | arm 1: Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 we... | [
0,
2
] | 3 | [
0,
0,
10
] | intervention 1: On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks. intervention 2... | intervention 1: Sildenafil citrate (open label) intervention 2: Testosterone gel intervention 3: Placebo gel | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 140 | 0 | 0 | 0 | NCT00512707 | 1COMPLETED | 2010-05-01 | 2006-11-01 | Boston University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 163 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This single arm study will assess the efficacy and safety of Mircera when administered once monthly, subcutaneously or intravenously, for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. Patients currently receiving maintenance treatment with epoetin alfa will receive monthly injecti... | null | Anemia | null | 1 | arm 1: Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta \[Mircera... | [
0
] | 1 | [
0
] | intervention 1: 120, 200 or 360 micrograms sc or iv monthly, starting dose | intervention 1: methoxy polyethylene glycol-epoetin beta [Mircera] | 28 | Buenos Aires | N/A | Argentina | -58.37723 | -34.61315
Buenos Aires | N/A | Argentina | -58.37723 | -34.61315
Buenos Aires | N/A | Argentina | -58.37723 | -34.61315
Buenos Aires | N/A | Argentina | -58.37723 | -34.61315
Córdoba | N/A | Argentina | -64.18853 | -31.40648
Santa Fe | N/A | Argentina | -60.70868 | -31.64881... | 162 | 0 | 0 | 0 | NCT00517413 | 1COMPLETED | 2010-05-01 | 2007-10-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 21 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This research study is being held at UCSD to determine whether the medication Quetiapine helps people suffering from anorexia nervosa by reducing core eating disorders symptoms. This study will see if the medication Quetiapine helps symptoms of anxiety, depression, and obsessionality, in addition to increasing BMI. Men... | null | Anorexia Nervosa | null | 2 | arm 1: The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2). arm 2: Secondary outcomes were to determine if quetiapine is superior to pl... | [
2,
0
] | 2 | [
0,
0
] | intervention 1: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a max... | intervention 1: Quetiapine intervention 2: Placebo | 1 | San Diego | California | United States | -117.16472 | 32.71571 | 15 | 0 | 0 | 0 | NCT00518973 | 1COMPLETED | 2010-05-01 | 2006-07-01 | University of California, San Diego | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 915 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied. | null | Type 2 Diabetes | Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Metformin Hypoglycemic Agents Pharmacologic Actions Physiological Effects of Drugs | null | 4 | arm 1: Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks arm 2: Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks arm 3: Participants received dapagliflozin, 5 mg, once daily... | [
2,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks intervention 2: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks intervention 3: Open-label metformin administered as ≥1500 mg per day for up to 102 weeks | intervention 1: Dapagliflozin intervention 2: Placebo intervention 3: Metformin | 75 | Tempe | Arizona | United States | -111.90931 | 33.41477
Encino | California | United States | -118.50119 | 34.15917
Fresno | California | United States | -119.77237 | 36.74773
Los Angeles | California | United States | -118.24368 | 34.05223
Northridge | California | United States | -118.53675 | 34.22834
San Diego | Cal... | 546 | 0 | 0 | 0 | NCT00528879 | 1COMPLETED | 2010-05-01 | 2007-09-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 42 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled trial. | null | Hepatic Encephalopathy | Minimal hepatic encephalopathy | null | 2 | arm 1: Will be given placebo and follow the exact procedures as the experimental section arm 2: None | [
2,
0
] | 2 | [
0,
0
] | intervention 1: 550mg BID rifaximin for 8 weeks intervention 2: same as the experimental arm | intervention 1: Rifaximin intervention 2: placebo | 1 | Richmond | Virginia | United States | -77.46026 | 37.55376 | 42 | 0 | 0 | 0 | NCT00533910 | 1COMPLETED | 2010-05-01 | 2007-10-01 | Hunter Holmes Mcguire Veteran Affairs Medical Center | 1FED | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 90 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The purpose of this study is to determine whether treating sleep difficulties in patients with bipolar disorder also improves their mood stability. | Patients with euthymic bipolar disorder, although free of significant mood symptoms, often have continued sleep disturbances. Improving patients' sleep by also normalizing the circadian rhythm will lead to fewer mood exacerbations. Ramelteon offers a new and more pharmacologically exact mechanism to re-synchronize the ... | Bipolar Disorder | null | 2 | arm 1: 8 mg arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: one 8 mg tablet at bedtime for up to 6 months intervention 2: one tablet at bedtime for up to 6 months | intervention 1: Ramelteon intervention 2: Placebo | 1 | Allentown | Pennsylvania | United States | -75.49018 | 40.60843 | 83 | 0 | 0 | 0 | NCT00552760 | 1COMPLETED | 2010-05-01 | 2007-11-01 | Lehigh Valley Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 210 | RANDOMIZED | PARALLEL | 2DIAGNOSTIC | 3TRIPLE | false | 0ALL | false | Determine the validity and compare the visualization of arterial segments obtained with 3 doses of iopamidol to determine dose for further investigation in future trials. | null | Coronary Artery Disease | null | 3 | arm 1: iopamidol injection 370, 70 mL arm 2: iopamidol injection 370, 80 mL arm 3: iopamidol injection 370, 90 mL | [
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: 70 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second intervention 2: 80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second intervention 3: 90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second | intervention 1: Isovue 370, 70 mL intervention 2: Isovue 370, 80 mL intervention 3: Isovue 370, 90 mL | 1 | Princeton | New Jersey | United States | -74.65905 | 40.34872 | 191 | 0 | 0 | 0 | NCT00558792 | 1COMPLETED | 2010-05-01 | 2007-11-01 | Bracco Diagnostics, Inc | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 121 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | true | The purpose of this study is to investigate how efficient TMC435350 will work against the Hepatitis C virus genotype 1 (genotypes refer to the genetic constitution of the virus) and what the concentrations of TMC435350 in the blood are with or without pegylated interferon alpha-2a (PegIFNa-2a) or PegIFNa-2a plus ribavi... | This is a blinded (participant and study staff will not know the identity of assigned treatments), randomized (participants assigned to treatment by chance), placebo-controlled (a term used to describe a method of research in which an inactive substance referred to as a placebo is given to one group of participants, wh... | Hepatitis C, Chronic | Hepatitis C, Chronic Tibotec TMC435350-TiDP16-C201 TMC435350-C201 TMC435 PEGASYS (peginterferon alpha-2a, PegIFNα-2a) COPEGUS (ribavirin) | null | 10 | arm 1: Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B). arm 2: Treatment-naïve particip... | [
0,
0,
2,
0,
2,
0,
0,
0,
2,
0
] | 4 | [
0,
0,
0,
0
] | intervention 1: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days. intervention 2: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days. intervention 3: One subcutaneous (under the skin) injection containing 0.5 mL ... | intervention 1: TMC435 intervention 2: Placebo intervention 3: Peginterferon (PegIFNα-2a) intervention 4: Ribavirin | 24 | Bruges | N/A | Belgium | 3.22424 | 51.20892
Brussels | N/A | Belgium | 4.34878 | 50.85045
Edegem | N/A | Belgium | 4.44504 | 51.15662
Ghent | N/A | Belgium | 3.71667 | 51.05
Clichy | N/A | France | 2.30952 | 48.90018
Lyon | N/A | France | 4.84671 | 45.74846
Marseille | N/A | France | 5.38107 | 43.29695
Paris | N/A | Fr... | 204 | 0 | 0 | 0 | NCT00561353 | 1COMPLETED | 2010-05-01 | 2008-01-01 | Tibotec Pharmaceuticals, Ireland | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 18 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | true | Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin. | One of the barriers to good glycemic control in children with type 1 diabetes is multiple daily insulin injections. Mixing rapid-acting (detemir) and slow- acting insulins (aspart) in the same syringe would decrease the number of injections and may improve adherence
This study hypothesized that slow-acting insulin det... | Type 1 Diabetes Mellitus | blood sugar glycemic | null | 2 | arm 1: Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days. arm 2: Participants first received Insulin Detemir and RAI as separate subcutaneous inj... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection intervention 2: Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection | intervention 1: Insulin Detemir mixed with RAI injection intervention 2: Insulin Detemir and RAI injection | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 28 | 0 | 0 | 0 | NCT00564395 | 1COMPLETED | 2010-05-01 | 2007-08-01 | Montefiore Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 210 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectiveness of the medication... | National and international asthma treatment guidelines recommend ICS as the initial controller therapy for people with asthma who are in need of daily treatment with a controller medication. If treatment with low to moderate doses of ICS is not sufficient to gain and maintain asthma control, current guidelines recommen... | Asthma | null | 6 | arm 1: Participants will take part in three 16-week treatment periods, which will occur in the following order:
* tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
* salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethaso... | [
0,
0,
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: tiotropium bromide inhalation powder 18 mcg once daily intervention 2: salmeterol xinafoate inhalation powder 50 mcg twice daily intervention 3: beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS) | intervention 1: tiotropium bromide intervention 2: salmeterol xinafoate intervention 3: beclomethasone dipropionate | 10 | San Diego | California | United States | -117.16472 | 32.71571
San Francisco | California | United States | -122.41942 | 37.77493
Denver | Colorado | United States | -104.9847 | 39.73915
Boston | Massachusetts | United States | -71.05977 | 42.35843
St Louis | Missouri | United States | -90.19789 | 38.62727
New York | N... | 594 | 0 | 0 | 0 | NCT00565266 | 1COMPLETED | 2010-05-01 | 2008-05-01 | Milton S. Hershey Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
5
] | 79 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | true | 0ALL | true | Older people living in nursing homes do not sleep very well for many reasons. Sleep disorders such as sleep apnea (when someone briefly stops breathing during sleep), and night time urination, along with the problems caused by the nighttime environment of the nursing home, such as noise and disruptive care routines can... | This study evaluates how well Ramelteon works by measuring sleep at night and during the day. After consenting and final determination of eligibility, participants will complete a baseline phase to assess usual sleep, as well as daytime alertness and activity , thinking and memory, walking and balance (among those who ... | Sleep Deprivation | Sleep hygiene Sleep latency Elderly sleep Nursing Home sleep | null | 2 | arm 1: SHI followed by Active Drug Ramelteon arm 2: SHI Followed by Placebo | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results. intervent... | intervention 1: Ramelteon intervention 2: Placebo | 0 | null | 22 | 0 | 0 | 0 | NCT00576927 | 1COMPLETED | 2010-05-01 | 2007-10-01 | Emory University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 147 | RANDOMIZED | PARALLEL | 7BASIC_SCIENCE | 2DOUBLE | false | 0ALL | false | Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patients with COPD | null | Chronic Obstructive Pulmonary Disease | null | 2 | arm 1: Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week t... | [
0,
2
] | 2 | [
0,
0
] | intervention 1: The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion. intervention 2: Matching placebo to ACZ885 administered via intravenous infusion. | intervention 1: Canakinumab intervention 2: Placebo | 11 | Anaheim | California | United States | -117.9145 | 33.83529
Los Angeles | California | United States | -118.24368 | 34.05223
Panama City | Florida | United States | -85.65983 | 30.15946
Marietta | Georgia | United States | -84.54993 | 33.9526
Baltimore | Maryland | United States | -76.61219 | 39.29038
Livonia | Michiga... | 147 | 0 | 0 | 0 | NCT00581945 | 1COMPLETED | 2010-05-01 | 2007-01-01 | Novartis | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2,
3
] | 3 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These trea... | Cicatricial pemphigoid is an autoimmune blistering disease which can affect the skin, mucous membranes, and, in a small subset of patients, the eyes. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments have included high dose systemic steroids, dapsone, and immunosuppressiv... | Ocular Cicatricial Pemphigoid | Pemphigoid Blistering Diseases Blindness Autoimmune Rituximab | null | 1 | arm 1: The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15). | [
0
] | 1 | [
0
] | intervention 1: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). | intervention 1: Rituximab | 1 | Birmingham | Alabama | United States | -86.80249 | 33.52066 | 3 | 0 | 0 | 0 | NCT00584935 | 1COMPLETED | 2010-05-01 | 2006-01-01 | University of Alabama at Birmingham | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 12 | RANDOMIZED | PARALLEL | null | 0NONE | true | 0ALL | false | The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor occupancy of armodafinil using positron emission tomography (PET) scanning with C-11 altropane as the ligand and 2) to document the increased intrasynaptic dopamine produced by armodafinil using PET scanning with C-11 raclopride ... | Modafinil produces a unique spectrum of pharmacological effects including enhanced vigilance, arousal, and wakefulness in human subjects (Bastuji and Jouvet 1988). The drug is widely used to treat narcolepsy (Banerjee, Vitiello et al. 2004), but is also effective in Attention Deficit Hyperactivity Disorder (ADHD) (Bied... | Healthy | Adults Healthy Volunteers Nuvigil Armodafinil DAT occupancy in healthy volunteers | null | 2 | arm 1: None arm 2: None | [
1,
1
] | 1 | [
0
] | intervention 1: tablet, taken by mouth, once each study day | intervention 1: armodafinil | 1 | Cambridge | Massachusetts | United States | -71.10561 | 42.3751 | 12 | 0 | 0 | 0 | NCT00592943 | 1COMPLETED | 2010-05-01 | 2007-10-01 | Massachusetts General Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 49 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone. | null | Diabetes Diabetes Mellitus, Type 2 | null | 3 | arm 1: Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12) arm 2: Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12) arm 3: Glimepiride 4 mg administered orally, on... | [
0,
2,
1
] | 3 | [
0,
0,
0
] | intervention 1: Stepwise dose increase, s.c. (under the skin) injection, once daily intervention 2: Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily intervention 3: Tablets, 1 - 4 mg daily | intervention 1: liraglutide intervention 2: placebo intervention 3: glimepiride | 1 | Rochester | Minnesota | United States | -92.4699 | 44.02163 | 49 | 0 | 0 | 0 | NCT00620282 | 1COMPLETED | 2010-05-01 | 2008-02-01 | Novo Nordisk A/S | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 1 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat hypertension by blocking the RAAS system have been developed. However, ... | The renin-angiotensin-aldosterone system (RAAS) plays a central role in the maintenance of normal blood pressure (BP) homeostasis. Derangements in the regulation of this system, predominantly due to the failure to appropriately suppress renin secretion by the kidney, contribute to the pathogenesis of hypertension and i... | Hypertension | null | 1 | arm 1: None | [
0
] | 2 | [
0,
0
] | intervention 1: 150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol. intervention 2: 50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameter... | intervention 1: Aliskiren intervention 2: Extended-release metoprolol | 1 | New York | New York | United States | -74.00597 | 40.71427 | 1 | 0 | 0 | 0 | NCT00627861 | 6TERMINATED | 2010-05-01 | 2008-11-01 | The Rogosin Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 1,095 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV). | null | Hepatitis C | Genotype 1 | null | 3 | arm 1: Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing ... | [
2,
0,
0
] | 4 | [
2,
0,
0,
10
] | intervention 1: subcutaneous injection, 180 micrograms once per week intervention 2: 375 mg tablets administered orally every 8 hours at a dose of 750 mg intervention 3: 200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg int... | intervention 1: Pegylated Interferon Alfa 2a intervention 2: Telaprevir intervention 3: Ribavirin intervention 4: Placebo | 116 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Birmingham | Alabama | United States | -86.80249 | 33.52066
Phoenix | Arizona | United States | -112.07404 | 33.44838
Fresno | California | United States | -119.77237 | 36.74773
La Jolla | California | United States | -117.2742 | 32.84727
Long Beach | Californ... | 1,088 | 0 | 0 | 0 | NCT00627926 | 1COMPLETED | 2010-05-01 | 2008-03-01 | Vertex Pharmaceuticals Incorporated | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 128 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF). | null | Idiopathic Pulmonary Fibrosis | Actelion Idiopathic Pulmonary Fibrosis bosentan Tracleer Interstitial Lung Disease BUILD 3 (NCT00391443) | null | 1 | arm 1: For patients who were administered bosentan during BUILD 3 (NCT00391443):
Same dose will continue
For patients who were administered placebo during BUILD 3 (NCT00391443):
Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg | [
0
] | 1 | [
0
] | intervention 1: For patients who were administered Bosentan during BUILD 3 (NCT00391443):
continue on same dose
For patients who were administered placebo during BUILD 3 (NCT00391443):
Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.) | intervention 1: Bosentan | 0 | null | 128 | 0 | 0 | 0 | NCT00631475 | 1COMPLETED | 2010-05-01 | 2008-04-01 | Actelion | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 73 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapi... | null | Follicular Lymphoma | null | 1 | arm 1: This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior ... | [
0
] | 3 | [
0,
0,
0
] | intervention 1: VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle. intervention 2: Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle intervention 3: Rituximab administered by IV infusion after... | intervention 1: VELCADE intervention 2: Bendamustine intervention 3: Rituximab | 2 | Washington D.C. | District of Columbia | United States | -77.03637 | 38.89511
Bismarck | North Dakota | United States | -100.78374 | 46.80833 | 73 | 0 | 0 | 0 | NCT00636792 | 1COMPLETED | 2010-05-01 | 2008-02-01 | Millennium Pharmaceuticals, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 29 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group. | The primary objective of the study is to assess the time to remission in depression with initial insomnia using the SSRI antidepressant escitalopram combined with ramelteon or placebo. Patients will be assessed at each visit for depressive symptoms and insomnia, using the 30-item Inventory of Depressive Symptoms, Clini... | Major Depressive Disorder Insomnia | MDD Major Depressive Disorder Depression Initial Insomnia sleep difficulty sleeping down sad Major Depressive Disorder(MDD) and initial insomnia | null | 2 | arm 1: Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night) arm 2: Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night) | [
0,
2
] | 3 | [
0,
0,
10
] | intervention 1: Escitalopram 10 or 20mg qd based on symptoms at patient visit intervention 2: Ramelteon 8 mg qd intervention 3: Matching placebo qd | intervention 1: Escitalopram intervention 2: Ramelteon intervention 3: Placebo | 1 | Dallas | Texas | United States | -96.80667 | 32.78306 | 29 | 0 | 0 | 0 | NCT00642694 | 6TERMINATED | 2010-05-01 | 2007-05-01 | University of Texas Southwestern Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 476 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | This study will assess the safety, tolerability and efficacy of RO4607381 in patients with coronary heart disease (CHD) or CHD risk equivalents. Patients will be randomized to receive either RO4607381 600mg po daily or placebo po daily. Endothelial function will be measured by flow mediated dilatation and blood pressur... | null | Coronary Heart Disease | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: po daily for 36 weeks intervention 2: 600mg po daily for 36 weeks | intervention 1: Placebo intervention 2: dalcetrapib | 23 | Feldkirch | N/A | Austria | 9.6 | 47.23306
Paris | N/A | France | 2.3488 | 48.85341
Bonn | N/A | Germany | 7.09549 | 50.73438
Dortmund | N/A | Germany | 7.466 | 51.51494
Frankfurt | N/A | Germany | 10.53333 | 49.68333
Mainz | N/A | Germany | 8.2791 | 49.98419
Wuppertal | N/A | Germany | 7.14816 | 51.25627
Pisa | Tuscan... | 472 | 0 | 0 | 0 | NCT00655538 | 1COMPLETED | 2010-05-01 | 2008-02-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 10 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | This study will evaluate HIV-HBV infected individuals who have evidence of HBV replication in the blood after taking 48 weeks of more of the HBV active medication tenofovir in combination with emtricitabine or lamivudine. Eligible participants will be randomized to receive 24 weeks of entecavir (ETV) 1 mg versus contin... | Design: This is a randomized, controlled pilot study of open-label entecavir for the treatment of persistent HBV viremia in HIV-HBV coinfected individuals who have failed to suppress HBV replication after 48 weeks on tenofovir containing therapy.
Primary Objective: To evaluate the mean log reduction of HBV DNA with en... | HIV Infections Hepatitis B | HIV Hepatitis B treatment experienced | null | 2 | arm 1: Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine arm 2: continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine | [
0,
1
] | 2 | [
0,
0
] | intervention 1: 1 mg by mouth daily intervention 2: continued standard of care with tenofovir in addition to emtricitabine or lamivudine | intervention 1: Entecavir with continued standard of care antiretroviral therapy intervention 2: continued standard of care with tenofovir in addition to emtricitabine or lamivudine | 1 | San Francisco | California | United States | -122.41942 | 37.77493 | 10 | 0 | 0 | 0 | NCT00662545 | 1COMPLETED | 2010-05-01 | 2008-04-01 | University of California, San Francisco | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 3 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial comparing three creams in the treatment of impetiginous eczema:
* Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
* Arm B: Combination of betamethasone diproprionate cream and gentamicin s... | null | Dermatitis, Atopic Eczema, Atopic Skin Diseases, Eczematous | Impetiginous | null | 3 | arm 1: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) arm 2: Combination of betamethasone diproprionate cream and gentamicin sulfate cream arm 3: Betamethasone diproprionate cream | [
0,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never mo... | intervention 1: Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) intervention 2: Cream (betamethasone diproprionate and gentamicin) intervention 3: Cream (betamethasone diproprionate) | 0 | null | 3 | 0 | 0 | 0 | NCT00671528 | 6TERMINATED | 2010-05-01 | 2009-07-01 | Organon and Co | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 25 | RANDOMIZED | PARALLEL | 4SUPPORTIVE_CARE | 0NONE | false | 0ALL | false | Oral and nasal steroids may enhance osteoporosis by suppressing bone formation. Intra-articular steroids may also suppress bone formation, however, the duration or relationship to a steroid dose has not been established. It is hypothesized that intra-articular steroids suppress bone formation transiently, returning to ... | Oral and nasal steroids may enhance osteoporosis by suppressing bone formation. Intra-articular steroids may also suppress bone formation, however, the duration or relationship to a steroid dose has not been established. It is hypothesized that intra-articular steroids suppress bone formation transiently, returning to ... | Osteoarthritis | Osteoarthritis, intra articular steroids | null | 3 | arm 1: Methylprednisone 80 mg and Lidocaine 20 mg arm 2: Methylprednisolone 16 mg and Lidocaine 20 mg arm 3: Placebo and Lidocaine 20 mg | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg intervention 2: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg intervention 3: Placebo and lidocaine 20 mg | intervention 1: Methylprednisolone and Lidocaine intervention 2: Methylprednisolone and Lidocaine intervention 3: Placebo and Lidocaine | 1 | Kansas City | Kansas | United States | -94.62746 | 39.11417 | 25 | 0 | 0 | 0 | NCT00682357 | 1COMPLETED | 2010-05-01 | 2008-05-01 | University of Kansas Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 12 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of the study is to evaluate in subjects suffering from nocturnal asthma, the efficacy and safety of modified release Prednisone on signs and symptoms. | Study with completed results acquired from Horizon in 2024. | Asthma | asthma nocturnal asthma glucocorticoid dependent persistent asthma signs and symptoms lung function prednisone | null | 2 | arm 1: After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients w... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period. intervention 2: Administered in the morning with food during the 4 week run-in period; patients remained on their respe... | intervention 1: Lodotra intervention 2: Cortancyl | 1 | Paris | N/A | France | 2.3488 | 48.85341 | 19 | 0 | 0 | 0 | NCT00686335 | 1COMPLETED | 2010-05-01 | 2008-06-01 | Amgen | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 216 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients. | null | Invasive Candidiasis | Candida Candidemia Systemic Candidiasis ICU Intensive Care Unit Critical Care Unit Anidulafungin Ecalta Eraxis Fluconazole Voriconazole | null | 1 | arm 1: Option to treat with oral azole therapy following treatment with anidulafungin | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Anidulafungin Intravenous Administration intervention 2: Oral Administration of Fluconazole intervention 3: Oral Administration of Voriconazole | intervention 1: Anidulafungin intervention 2: Fluconazole intervention 3: Voriconazole | 61 | Vienna | N/A | Austria | 16.37208 | 48.20849
Brussels | N/A | Belgium | 4.34878 | 50.85045
Brussels | N/A | Belgium | 4.34878 | 50.85045
Ghent | N/A | Belgium | 3.71667 | 51.05
Leuven | N/A | Belgium | 4.70093 | 50.87959
Liège | N/A | Belgium | 5.56749 | 50.63373
Yvoir | N/A | Belgium | 4.88059 | 50.3279
Hamilton | Ont... | 216 | 0 | 0 | 0 | NCT00689338 | 1COMPLETED | 2010-05-01 | 2008-07-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 100 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to explore whether LY2127399 is effective in relieving signs and symptoms of rheumatoid arthritis (RA) in patients with a history of inadequate response or intolerance to at least 1 Tumor Necrosis Factor-Alpha (TNFα) inhibitor therapy. Examples of these TNFα inhibitor therapies that are cur... | null | Arthritis, Rheumatoid | null | 3 | arm 1: Double-blind Treatment: 30 mg LY2127399 administered as a single intravenous (IV) infusion over 30 minutes at 0, 3, and 6 weeks.
Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded)... | [
0,
0,
2
] | 2 | [
2,
0
] | intervention 1: LY2127399 will be administered as a single IV infusion over 30 minutes. intervention 2: Placebo will be administered as a single IV infusion over 30 minutes. | intervention 1: LY2127399 intervention 2: Placebo | 45 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Mesa | Arizona | United States | -111.82264 | 33.42227
Palm Desert | California | United States | -116.37697 | 33.72255
Riverside | California | United States | -117.39616 | 33.95335
Santa Maria | California | United States | -120.43572 | 34.95303
Upland | Cal... | 217 | 0 | 0 | 0 | NCT00689728 | 1COMPLETED | 2010-05-01 | 2008-06-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
4
] | 669 | NON_RANDOMIZED | null | 0TREATMENT | 0NONE | false | 0ALL | false | This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension. | Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause ... | Hypertension | Essential Hypertension Cardiovascular Disease High Blood Pressure Drug Therapy | null | 1 | arm 1: None | [
0
] | 2 | [
0,
0
] | intervention 1: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target ... | intervention 1: Azilsartan medoxomil with or without add-on chlorthalidone intervention 2: Azilsartan medoxomil with or without add-on hydrochlorothiazide | 41 | Ozark | Alabama | United States | -85.64049 | 31.45906
Tallassee | Alabama | United States | -85.89329 | 32.53597
Long Beach | California | United States | -118.18923 | 33.76696
Santa Rosa | California | United States | -122.71443 | 38.44047
Spring Valley | California | United States | -116.99892 | 32.74477
Colorado Sp... | 669 | 0 | 0 | 0 | NCT00695955 | 1COMPLETED | 2010-05-01 | 2007-06-01 | Takeda | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 68 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | This study is meant to assess the safety and tolerability of idebenone in patients with Friedreich's Ataxia over a 12 months period. | The study involves 6 clinic visits. | Friedreich's Ataxia | Friedreich's Ataxia Idebenone ICARS | null | 1 | arm 1: high dose Idebenone | [
0
] | 1 | [
0
] | intervention 1: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day | intervention 1: Idebenone | 2 | Los Angeles | California | United States | -118.24368 | 34.05223
Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 68 | 0 | 0 | 0 | NCT00697073 | 1COMPLETED | 2010-05-01 | 2008-07-01 | Santhera Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 50 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung ... | null | Recurrent Small-cell Lung Cancer (SCLC) Lung Cancer, Small Cell | Bevacizumab Small Cell Lung Cancer (SCLC) Topotecan | null | 1 | arm 1: Oral topotecan + IV Bevacizumab | [
0
] | 1 | [
0
] | intervention 1: 2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle. | intervention 1: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) | 16 | Jonesboro | Arkansas | United States | -90.70428 | 35.8423
Gainesville | Florida | United States | -82.32483 | 29.65163
Naples | Florida | United States | -81.79596 | 26.14234
Athens | Georgia | United States | -83.37794 | 33.96095
Macon | Georgia | United States | -83.6324 | 32.84069
Marietta | Georgia | United States... | 50 | 0 | 0 | 0 | NCT00698516 | 1COMPLETED | 2010-05-01 | 2008-07-01 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 137 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects. | null | Conjunctivitis | Blepharokeratoconjunctivitis | null | 4 | arm 1: Drug: Zylet (loteprednol etabonate and tobramycin) arm 2: Drug: Lotemax (loteprednol etabonate) arm 3: Drug: Tobramycin arm 4: Vehicle of Zylet | [
0,
1,
1,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days. intervention 2: Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days. intervention 3: Topical ocular administration of Tobramycin QID for 14 days. intervention 4: Topical ... | intervention 1: loteprednol etabonate and tobramycin intervention 2: loteprednol etabonate intervention 3: Tobramycin intervention 4: Vehicle of Zylet | 1 | Erie | Pennsylvania | United States | -80.08506 | 42.12922 | 136 | 0 | 0 | 0 | NCT00705159 | 1COMPLETED | 2010-05-01 | 2008-06-01 | Bausch & Lomb Incorporated | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 141 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated with MTX monotherapy, but continue to have moderate disease activity. | null | Rheumatoid Arthritis | Moderate Rheumatoid Arthritis | null | 2 | arm 1: Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold). arm 2: Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-fi... | [
1,
1
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: etanercept (EnbrelTM) intervention 2: methotrexate | 45 | Ostrava | N/A | Czechia | 18.28204 | 49.83465
Prague | N/A | Czechia | 14.42076 | 50.08804
Prague | N/A | Czechia | 14.42076 | 50.08804
Amiens | N/A | France | 2.3 | 49.9
Échirolles | N/A | France | 5.71441 | 45.14603
Metz | N/A | France | 6.17269 | 49.11911
Montpellier | N/A | France | 3.87635 | 43.61093
Paris | N/A |... | 134 | 0 | 0 | 0 | NCT00706797 | 6TERMINATED | 2010-05-01 | 2008-09-01 | Wyeth is now a wholly owned subsidiary of Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 124 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease (CAD) who are already on a stable dose of other lipid-lowering agents (including maximally... | Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder of lipoprotein metabolism characterized by markedly elevated LDL-C, premature onset of atherosclerosis and development of xanthomata. Patients with heterozygous familial hypercholesterolemia typically have total plasma cholesterol between 350 ... | Heterozygous Familial Hypercholesterolemia Coronary Artery Disease | familial hypercholesterolemia | null | 2 | arm 1: Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks. arm 2: Participants received a placebo subcutaneous injection once a week for 26 weeks. | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 200 mg /mL intervention 2: 1 mL matching placebo | intervention 1: mipomersen sodium intervention 2: placebo | 48 | La Jolla | California | United States | -117.2742 | 32.84727
Los Angeles | California | United States | -118.24368 | 34.05223
Mission Viejo | California | United States | -117.672 | 33.60002
Newport Beach | California | United States | -117.92895 | 33.61891
Santa Ana | California | United States | -117.86783 | 33.74557... | 124 | 0 | 0 | 0 | NCT00706849 | 1COMPLETED | 2010-05-01 | 2008-07-01 | Kastle Therapeutics, LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.